

**Clinical trial results:**

**A phase III double-blind, cluster-randomized, controlled study to evaluate the impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals' 10-valent pneumococcal and non-typeable Haemophilus influenzae protein D conjugate vaccine in children starting vaccination below 18 months of age.**

**Summary**

EudraCT number	2008-006551-51
Trial protocol	FI
Global end of trial date	31 January 2012

**Results information**

Result version number	v4 (current)
This version publication date	02 January 2021
First version publication date	30 July 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Results have been amended to account for consistency with other registries.

**Trial information****Trial identification**

Sponsor protocol code	112595
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00839254
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89,, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000673-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 April 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	31 January 2012
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate the effectiveness of 10Pn-PD-DiT vaccine in preventing culture-confirmed IPD due to vaccine pneumococcal serotypes in children vaccinated with at least one dose of 10Pn-PD-DiT within the first 7 months of life in clusters assigned to a 3-dose primary vaccination course.

Criteria for effectiveness: Effectiveness (VE) in preventing culture-confirmed IPD due to the 10 vaccine serotypes will be demonstrated if the 2-sided p-value calculated for the null hypothesis  $H_0 = (\text{vaccine-type [VT] IPD VE} = 0\%)$  is lower than 5%. Refer to 10PN-PD-DIT-043 study (EudraCT number : 2008-005149-48).

Protection of trial subjects:

Vaccinees were observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed up for serious adverse events (SAEs) reported as occurring during the study up to study end. An Independent Data Monitoring Committee (IDMC) was set up for this study to protect the ethical and safety interests of the subjects recruited, while securing as much as possible the scientific validity of the data. The IDMC was the same as in the 10PN-PD-DIT-043 study and will review safety data (SAEs) and all-cause mortality to identify potential treatment harm/benefit. Responsibilities of the IDMC included the following: 1) Review of data collection methods, safety/effectiveness monitoring procedures and making recommendations for additions or adjustments, as applicable.; 2) Recommendations for maintaining, or breaking the blind where necessary, in the course of reviewing the results; 3) Recommendations for stopping the trial for effectiveness or safety reasons when appropriate.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 February 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	9 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 54088
Worldwide total number of subjects	54088
EEA total number of subjects	54088

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	54088
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study is linked with 10PN-PD-DIT-043 (111442) study (NCT00861380.-EudraCT: 2008-005149-48) with which primary objectives and outcomes are common. Subjects of 10PN-PD-DIT-043 study contributed to the results of this study.

### Pre-assignment

Screening details:

Out of 6183 subjects enrolled, 6177 were analyzed:(6174 subjects and 3 of them received 2 subject numbers, without any impact on the results of the analyses). Total population assessed for combined analyses performed on both studies included 45977 subjects, see details in groups description.

### Pre-assignment period milestones

Number of subjects started	54088
Number of subjects completed	6177

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	10PN043-053 subjects: 45977
Reason: Number of subjects	Control 6W-6M pooled group: 1928
Reason: Number of subjects	Consent withdrawn by subject: 6

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

This study was conducted in a double-blind fashion for vaccine/control clusters applying the same 2+1 and 3+1 infant schedules. Study was run in an open fashion between infant schedules.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	10Pn3+1-6W-6M/053 Group

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

<b>Arm title</b>	10Pn2+1-6W-6M/053 Group
------------------	-------------------------

**Arm description:**

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscularly administration by injection in the thigh.

<b>Arm title</b>	Ctrl3+1-6W-6M/053 Group
------------------	-------------------------

**Arm description:**

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Active comparator
Investigational medicinal product name	Engerix B-thio free
Investigational medicinal product code	
Other name	Engerix-B,HBV
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscularly administration by injection in the thigh.

<b>Arm title</b>	Ctrl2+1-6W-6M/053 Group
------------------	-------------------------

**Arm description:**

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Active comparator
Investigational medicinal product name	Engerix B-thio free
Investigational medicinal product code	
Other name	Engerix-B,HBV
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscularly administration by injection in the thigh.

<b>Arm title</b>	10Pn7-11M/053 Group
------------------	---------------------

**Arm description:**

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

<b>Arm title</b>	Ctrl7-11M/053 Group
------------------	---------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm type	Active comparator
Investigational medicinal product name	Engerix B-thio free
Investigational medicinal product code	
Other name	Engerix-B,HBV
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

<b>Arm title</b>	10Pn12-18M/053 Group
------------------	----------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

<b>Arm title</b>	Ctrl12-18M/053 Group
------------------	----------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Havrix-preservative free
Investigational medicinal product code	
Other name	HAV, Havrix 720 Junior
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

<b>Number of subjects in period 1<sup>[1]</sup></b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group
Started	1849	1316	1069
Completed	1696	1224	979
Not completed	153	92	90
Consent withdrawn by subject	87	53	54
Parents wanted pneumococcal vaccine	1	-	-
Physician decision	-	1	-
Adverse event, non-fatal	12	6	3
Withdrawn due to non-compliance	2	-	-
Wrong group allocation	-	-	-
Wrong treatment number allocation	-	1	-
Lost to follow-up	51	30	32
Protocol deviation	-	1	1

<b>Number of subjects in period 1<sup>[1]</sup></b>	Ctrl2+1-6W-6M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Started	859	241	204
Completed	797	204	178
Not completed	62	37	26
Consent withdrawn by subject	32	27	15
Parents wanted pneumococcal vaccine	-	-	1
Physician decision	-	-	-
Adverse event, non-fatal	5	2	1
Withdrawn due to non-compliance	-	-	-
Wrong group allocation	-	-	-
Wrong treatment number allocation	-	-	1
Lost to follow-up	24	8	8
Protocol deviation	1	-	-

<b>Number of subjects in period 1<sup>[1]</sup></b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group
Started	368	271

Completed	340	256
Not completed	28	15
Consent withdrawn by subject	22	9
Parents wanted pneumococcal vaccine	-	-
Physician decision	-	1
Adverse event, non-fatal	-	1
Withdrawn due to non-compliance	-	-
Wrong group allocation	1	-
Wrong treatment number allocation	-	-
Lost to follow-up	4	2
Protocol deviation	1	2

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 6183 subjects in total were enrolled in this study, out of which 6177 were actually vaccinated in this study. In addition to these, the Total population assessed for combined analyses performed on both studies included 45977 subjects and an additional pooled group- subjects analysis set has to be defined for the 6W-6M Control group for presenting carriage data.

## Baseline characteristics

### Reporting groups

Reporting group title	10Pn3+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn2+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl3+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl2+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn7-11M/053 Group
-----------------------	---------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	Ctrl7-11M/053 Group
-----------------------	---------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	10Pn12-18M/053 Group
-----------------------	----------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	Ctrl12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

<b>Reporting group values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group
Number of subjects	1849	1316	1069
Age categorical Units:			
28 days - 23 months	1849	1316	1069
Age Continuous Units: Months			
arithmetic mean	2.4	2.3	2.6
standard deviation	± 1.02	± 0.95	± 1.19
Sex: Female, Male Units: Participants			
Female	921	681	551
Male	928	635	518
Race/Ethnicity, Customized Units: Subjects			
African heritage / African American	1	0	0
White - Arabic / north African heritage	7	5	4
White - Caucasian / European heritage	1822	1303	1058
Unspecified	19	8	7

<b>Reporting group values</b>	Ctrl2+1-6W-6M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Number of subjects	859	241	204
Age categorical Units:			
28 days - 23 months	859	241	204
Age Continuous Units: Months			
arithmetic mean	2.4	9	8.7
standard deviation	± 1	± 1.44	± 1.39
Sex: Female, Male Units: Participants			
Female	393	118	113
Male	466	123	91
Race/Ethnicity, Customized Units: Subjects			
African heritage / African American	0	1	1
White - Arabic / north African heritage	6	3	0
White - Caucasian / European heritage	845	235	201
Unspecified	8	2	2

<b>Reporting group values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group	Total
Number of subjects	368	271	6177
Age categorical Units:			
28 days - 23 months	368	271	6177
Age Continuous Units: Months			
arithmetic mean	15	15.2	
standard deviation	± 1.99	± 1.99	-
Sex: Female, Male Units: Participants			
Female	173	142	3092
Male	195	129	3085
Race/Ethnicity, Customized Units: Subjects			
African heritage / African American	2	0	5
White - Arabic / north African heritage	2	0	27
White - Caucasian / European heritage	362	270	6096
Unspecified	2	1	49

## End points

### End points reporting groups

Reporting group title	10Pn3+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn2+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl3+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl2+1-6W-6M/053 Group
-----------------------	-------------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn7-11M/053 Group
-----------------------	---------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	Ctrl7-11M/053 Group
-----------------------	---------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	10Pn12-18M/053 Group
-----------------------	----------------------

#### Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	Ctrl12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Subject analysis set title	10Pn3+1-6W-6M/043+053 Group
----------------------------	-----------------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 8427 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, or 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). Refer to group description for 10Pn3+1-6W-6M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	10Pn2+1-6W-6M/043+053 Group
----------------------------	-----------------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 9112 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, or 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). Refer to group description for 10Pn2+1-6W-6M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl-6W-6M/043+053 Group
----------------------------	--------------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 8872 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). Refer to group descriptions for Ctrl3+1-6W-6M/053 and Ctrl2+1-6W-6M/053 groups for details on vaccine specifics and administration route in this group.

Subject analysis set title	10Pn7-11M/043+053 Group
----------------------------	-------------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 3689 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, or 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). Refer to group description for 10Pn7-11M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl7-11M/043+053 Group
----------------------------	-------------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 1812 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). Refer to group description for Ctrl7-11M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	10Pn12-18M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 6249 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, or 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). Refer to group description for 10Pn12-18M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl12-18M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects analyzed among all subjects who were enrolled in this group in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) (i.e. 3020 subjects) and 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) studies and aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). Refer to group description for Ctrl12-18M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl-6W-6M/053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 EUDRACT 2008-006551-51) studies and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). Refer to group descriptions for Ctrl3+1-6W-6M/053 and Ctrl2+1-6W-6M/053 groups for details on vaccine specifics and administration route in this group.

**Primary: Person Year Rate as regards subjects with culture-confirmed IPD due to any of the 10 pneumococcal vaccine serotypes. In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.**

End point title	Person Year Rate as regards subjects with culture-confirmed IPD due to any of the 10 pneumococcal vaccine serotypes. In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	--

End point description:

The PYAR (Person-Year Rate) as regards subjects with culture-confirmed invasive pneumococcal disease (IPD) due to any of the pneumococcal vaccine serotypes was tabulated (vaccine pneumococcal serotypes = serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F). PYAR was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Primary
----------------	---------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

<b>End point values</b>	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	0.000 (0.000 to 0.172)	0.564 (0.291 to 0.984)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical analysis 1
Statistical analysis description:	
Analysis aimed at providing an estimate of vaccine effectiveness (VE) at preventing culture-confirmed IPD by comparing PYARs between groups taking into account the following parameters: T, n, n+ (number of clusters with at least one event culture-confirmed ID), and n/T. VE of the 10Pn vaccine in preventing culture-confirmed IPD due to the 10 vaccine serotypes was demonstrated if the 2-sided p-value calculated for the null hypothesis H0 = (vaccine-type [VT] IPD VE = 0%) was lower than (<) 5%.	
Comparison groups	10Pn3+1-6W-6M/043+053 Group v Ctrl-6W-6M/043+053 Group
Number of subjects included in analysis	20474
Analysis specification	Pre-specified
Analysis type	superiority <sup>[1]</sup>
P-value	< 0.0001 <sup>[2]</sup>
Method	Regression, Linear
Parameter estimate	VE (1-RR)
Point estimate	100
Confidence interval	
level	95 %
sides	2-sided
lower limit	82.8
upper limit	100

Notes:

[1] - VE (defined as 1 minus Relative Risk (RR)) was calculated by comparing numbers of culture-confirmed IPD. The number of subjects with IPD in each cluster was compared between groups (10PN3+1 vs Control). This comparison was done using a negative binomial log-linear model with correction for dispersion group- and cluster-related effect.

[2] - P-value was calculated using a classical log linear Poisson regression with strata, without taking into account the multiplicity of the endpoints.

### **Primary: Person Year Rate as regards subjects with culture-confirmed IPD due to any of the 10 pneumococcal vaccine serotypes. In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.**

End point title	Person Year Rate as regards subjects with culture-confirmed IPD due to any of the 10 pneumococcal vaccine serotypes. In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	--

End point description:

The PYAR (Person-Year Rate) as regards subjects with culture-confirmed invasive pneumococcal disease (IPD) due to any of the pneumococcal vaccine serotypes was tabulated (vaccine pneumococcal serotypes = serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F). PYAR was calculated as follows n (= number of subjects reported with a culture confirmed IPD) divided by T (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Primary
----------------	---------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

End point values	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	0.048 (0.001 to 0.270)	0.564 (0.291 to 0.984)		

## Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Analysis aimed at providing an estimate of vaccine effectiveness (VE) at preventing culture-confirmed IPD by comparing PYARs between groups taking into account the following parameters: T, n, n+ (number of clusters with at least one event culture-confirmed ID), and n/T. VE of the 10Pn vaccine in preventing culture-confirmed IPD due to the 10 vaccine serotypes was demonstrated if the 2-sided p-value calculated for the null hypothesis H0 = (vaccine-type [VT] IPD VE = 0%) was lower than (<) 5%.	
Comparison groups	10Pn2+1-6W-6M/043+053 Group v Ctrl-6W-6M/043+053 Group
Number of subjects included in analysis	20255
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.0009 <sup>[4]</sup>
Method	Regression, Linear
Parameter estimate	VE (1-RR)
Point estimate	91.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	58.3
upper limit	99.6

Notes:

[3] - VE (defined as 1 minus Relative Risk (RR)) was calculated by comparing numbers of culture-confirmed IPD. The number of subjects with IPD in each cluster was compared between groups (10PN2+1 vs Control). This comparison was done using a negative binomial log-linear model with correction for dispersion group- and cluster-related effect.

[4] - p-value was calculated using a classical log linear Poisson regression with strata, without taking into account the multiplicity of the endpoints.

### **Secondary: Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.**

End point title	Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	--

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type Secondary

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

End point values	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Culture confirmed ID	0.093 (0.011 to 0.336)	0.845 (0.501 to 1.336)		
Pneumococcal invasive disease (IPD)	0.000 (0.000 to 0.172)	0.657 (0.359 to 1.103)		
Serotype 4	0.000 (0.000 to 0.172)	0.000 (0.000 to 0.173)		
Serotype 6B	0.000 (0.000 to 0.172)	0.235 (0.076 to 0.548)		
Serotype 7F	0.000 (0.000 to 0.172)	0.000 (0.000 to 0.173)		
Serotype 14	0.000 (0.000 to 0.172)	0.188 (0.051 to 0.481)		
Serotype 18C	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Serotype 19F	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Serotype 23F	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Cross-reactive serotypes	0.000 (0.000 to 0.172)	0.094 (0.011 to 0.339)		
Serotype 6A	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Serotype 19A	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Other pneumococcal serotypes	0.000 (0.000 to 0.172)	0.000 (0.000 to 0.173)		
Serotype 3	0.000 (0.000 to 0.172)	0.000 (0.000 to 0.173)		
Serotype 15C	0.000 (0.000 to 0.172)	0.000 (0.000 to 0.173)		
H. influenzae ID	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Non-typeable (NTHI)	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
Other bacteria	0.093 (0.011 to 0.336)	0.188 (0.051 to 0.481)		
Neisseria meningitidis	0.093 (0.011 to 0.336)	0.047 (0.001 to 0.262)		
Streptococcus pyogenes	0.000 (0.000 to 0.172)	0.094 (0.011 to 0.339)		

Moraxella catarrhalis	0.000 (0.000 to 0.172)	0.047 (0.001 to 0.262)		
-----------------------	------------------------	------------------------	--	--

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.

End point title	Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	--

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

End point values	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Culture confirmed ID	0.194 (0.053 to 0.496)	0.845 (0.501 to 1.336)		
Pneumococcal invasive disease (IPD)	0.097 (0.012 to 0.350)	0.657 (0.359 to 1.103)		
Vaccine serotypes (vaccine type-IPD)	0.048 (0.001 to 0.270)	0.564 (0.291 to 0.984)		
Serotype 4	0.000 (0.000 to 0.179)	0.000 (0.000 to 0.173)		
Serotype 6B	0.000 (0.000 to 0.179)	0.235 (0.076 to 0.548)		
Serotype 7F	0.048 (0.001 to 0.270)	0.000 (0.000 to 0.173)		
Serotype 14	0.000 (0.000 to 0.179)	0.188 (0.051 to 0.481)		
Serotype 18C	0.000 (0.000 to 0.179)	0.047 (0.001 to 0.262)		
Serotype 19F	0.000 (0.000 to 0.179)	0.047 (0.001 to 0.262)		
Serotype 23F	0.000 (0.000 to 0.179)	0.047 (0.001 to 0.262)		

Cross-reactive serotypes	0.000 (0.000 to 0.179)	0.094 (0.011 to 0.339)		
Serotype 6A	0.000 (0.000 to 0.179)	0.047 (0.001 to 0.262)		
Serotype 19A	0.000 (0.000 to 0.179)	0.047 (0.001 to 0.262)		
Other pneumococcal serotypes	0.048 (0.001 to 0.270)	0.000 (0.000 to 0.173)		
Serotype 3	0.048 (0.001 to 0.270)	0.000 (0.000 to 0.173)		
Serotype 15C	0.000 (0.000 to 0.179)	0.000 (0.000 to 0.173)		
H. influenzae ID	0.048 (0.001 to 0.270)	0.047 (0.001 to 0.262)		
Non-typeable (NTHI)	0.048 (0.001 to 0.270)	0.047 (0.001 to 0.262)		
Other bacteria	0.048 (0.001 to 0.270)	0.188 (0.051 to 0.481)		
Neisseria meningitidis	0.048 (0.001 to 0.270)	0.047 (0.001 to 0.262)		
Streptococcus pyogenes	0.000 (0.000 to 0.179)	0.094 (0.011 to 0.339)		
Moraxella catarrhalis	0.000 (0.000 to 0.179)	0.047 (0.001 to 0.262)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination in the 7-11 months schedule.

End point title	Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination in the 7-11 months schedule.
-----------------	--

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

End point values	10Pn7-11M/043+053 Group	Ctrl7-11M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3880	1908		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				

Culture confirmed ID	0.000 (0.000 to 0.410)	0.446 (0.054 to 1.612)		
Pneumococcal invasive disease (IPD)	0.000 (0.000 to 0.410)	0.446 (0.054 to 1.612)		
Vaccine serotypes (vaccine type-IPD)	0.000 (0.000 to 0.410)	0.446 (0.054 to 1.612)		
Serotype 4	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 6B	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 7F	0.000 (0.000 to 0.410)	0.223 (0.006 to 1.243)		
Serotype 14	0.000 (0.000 to 0.410)	0.223 (0.006 to 1.243)		
Serotype 18C	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 19F	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 23F	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Cross-reactive serotypes	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 6A	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 19A	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Other pneumococcal serotypes	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 3	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Serotype 15C	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
H. influenzae ID	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Non-typeable (NTHI)	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Other bacteria	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination in the 12-18 months schedule.

End point title	Person Year Rate in the prevention of culture-confirmed invasive disease (ID)- In children starting vaccination in the 12-18 months schedule.
-----------------	---

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

<b>End point values</b>	10Pn12- 18M/043+053 Group	Ctrl12- 18M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6535	3126		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Culture confirmed ID	0.000 (0.000 to 0.240)	0.674 (0.219 to 1.572)		
Pneumococcal invasive disease (IPD)	0.000 (0.000 to 0.240)	0.674 (0.219 to 1.572)		
Vaccine serotypes (vaccine type-IPD)	0.000 (0.000 to 0.240)	0.404 (0.083 to 1.181)		
Serotype 4	0.000 (0.000 to 0.240)	0.135 (0.003 to 0.751)		
Serotype 6B	0.000 (0.000 to 0.240)	0.135 (0.003 to 0.751)		
Serotype 7F	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Serotype 14	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Serotype 18C	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Serotype 19F	0.000 (0.000 to 0.240)	0.135 (0.003 to 0.751)		
Serotype 23F	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Cross-reactive serotypes	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Serotype 6A	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Serotype 19A	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Other pneumococcal serotypes	0.000 (0.000 to 0.240)	0.269 (0.033 to 0.974)		
Serotype 3	0.000 (0.000 to 0.240)	0.135 (0.003 to 0.751)		
Serotype 15C	0.000 (0.000 to 0.240)	0.135 (0.003 to 0.751)		
H. influenzae ID	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Non-typeable (NTHI)	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Other bacteria	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Person Year Rate in the prevention of probable culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and

---

**assigned to a 3-dose primary vaccination course.**

---

End point title	Person Year Rate in the prevention of probable culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	---

## End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a probable or culture confirmed ID) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

## End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

---

End point values	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Probable cases of IPD	0.000 (0.000 to 0.172)	0.141 (0.029 to 0.412)		
Confirmed or probable cases of IPD	0.000 (0.000 to 0.172)	0.798 (0.465 to 1.278)		

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Person Year Rate in the prevention of probable or culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.**

---

End point title	Person Year Rate in the prevention of probable or culture-confirmed invasive disease (ID)- In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	--

## End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a probable or culture confirmed ID) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

## End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

---

<b>End point values</b>	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Probable cases of IPD	0.000 (0.000 to 0.179)	0.141 (0.029 to 0.412)		
Confirmed or probable cases of IPD	0.097 (0.012 to 0.350)	0.798 (0.465 to 1.278)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in the prevention of probable or culture-confirmed invasive disease (ID)- In children starting vaccination in the 7-11 months schedule.

End point title	Person Year Rate in the prevention of probable or culture-confirmed invasive disease (ID)- In children starting vaccination in the 7-11 months schedule.
-----------------	--

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a probable or culture confirmed ID) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

<b>End point values</b>	10Pn7-11M/043+053 Group	Ctrl7-11M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3880	1908		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Probable cases of IPD	0.000 (0.000 to 0.410)	0.000 (0.000 to 0.823)		
Confirmed or probable cases of IPD	0.000 (0.000 to 0.410)	0.446 (0.054 to 1.612)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Person Year Rate in the prevention of probable or culture-confirmed invasive disease (ID)- In children starting vaccination in the 12-18 months schedule.**

End point title	Person Year Rate in the prevention of probable or culture-confirmed invasive disease (ID)- In children starting vaccination in the 12-18 months schedule.
-----------------	---

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a probable or culture confirmed ID) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months).

End point values	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6535	3126		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Probable cases of IPD	0.000 (0.000 to 0.240)	0.000 (0.000 to 0.497)		
Confirmed or probable cases of IPD	0.000 (0.000 to 0.240)	0.674 (0.219 to 1.572)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.**

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. Hospital-diagnosed pneumonia (HDP) cases identified based on hospital discharge diagnosis using international Classification of Disease (ICD)-10 diagnosis codes: J10.0 (Influenza with HDP, other influenza virus identified), J11.0 (Influenza with HDP, virus not identified), J12 (Viral HDP, not elsewhere classified), J13 (HDP due to Sp.), J14 (for HDP due to Hi.), J15 (all HDP, not elsewhere classified), J16 (HDP due to other infectious organisms, not elsewhere classified), J17 (HDP in diseases classified elsewhere), J18 (HDP organism unspecified), J85.1 (Abscess of lung with HDP), and J86 (Pyothorax including empyema).

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the

<b>End point values</b>	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	10.131 (8.804 to 11.601)	13.854 (12.287 to 15.566)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. Hospital-diagnosed pneumonia (HDP) cases identified based on hospital discharge diagnosis using international Classification of Disease (ICD)-10 diagnosis codes: J10.0 (Influenza with HDP, other influenza virus identified), J11.0 (Influenza with HDP, virus not identified), J12 (Viral HDP, not elsewhere classified), J13 (HDP due to Sp.), J14 (for HDP due to Hi.), J15 (all HDP, not elsewhere classified), J16 (HDP due to other infectious organisms, not elsewhere classified), J17 (HDP in diseases classified elsewhere), J18 (HDP organism unspecified), J85.1 (Abscess of lung with HDP), and J86 (Pyothorax including empyema).

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.

<b>End point values</b>	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	10.155 (8.800 to 11.660)	13.854 (12.287 to 15.566)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia- In children starting vaccination in the 7-11 months schedule.

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia- In children starting vaccination in the 7-11 months schedule.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. Hospital-diagnosed pneumonia (HDP) cases identified based on hospital discharge diagnosis using international Classification of Disease (ICD)-10 diagnosis codes: J10.0 (Influenza with HDP, other influenza virus identified), J11.0 (Influenza with HDP, virus not identified), J12 (Viral HDP, not elsewhere classified), J13 (HDP due to Sp.), J14 (for HDP due to Hi.), J15 (all HDP, not elsewhere classified), J16 (HDP due to other infectious organisms, not elsewhere classified), J17 (HDP in diseases classified elsewhere), J18 (HDP organism unspecified), J85.1 (Abscess of lung with HDP), and J86 (Pyothorax including empyema).

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

End point values	10Pn7-11M/043+053 Group	Ctrl7-11M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3880	1907		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	10.263 (8.242 to 12.630)	15.752 (12.232 to 19.970)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia - In children starting vaccination in the 12-18 months schedule.

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia - In children starting vaccination in the 12-18 months schedule.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia) divided by  $T$  (= sum

of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. Hospital-diagnosed pneumonia (HDP) cases identified based on hospital discharge diagnosis using international Classification of Disease (ICD)-10 diagnosis codes: J10.0 (Influenza with HDP, other influenza virus identified), J11.0 (Influenza with HDP, virus not identified), J12 (Viral HDP, not elsewhere classified), J13 (HDP due to Sp.), J14 (for HDP due to Hi.), J15 (all HDP, not elsewhere classified), J16 (HDP due to other infectious organisms, not elsewhere classified), J17 (HDP in diseases classified elsewhere), J18 (HDP organism unspecified), J85.1 (Abscess of lung with HDP), and J86 (Pyothorax including empyema).

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

End point values	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6534	3126		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	9.322 (7.832 to 11.013)	11.739 (9.363 to 14.533)		

## Statistical analyses

No statistical analyses for this end point

### **Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia with Chest X-ray (CXR) reading according to WHO criteria- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.**

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia with Chest X-ray (CXR) reading according to WHO criteria- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia [HDP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata for non-consolidated HDP and without strata for consolidated HDP). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. CXR HDP was defined as a HDP case with the presence of abnormal pulmonary infiltrates on the CXR as per independent review panel judgement using WHO methodology. Abnormal pulmonary infiltrates could be either with (Consolidated HDP) or without (Non-consolidated HDP) alveolar consolidation/pleural effusion. New cases of HDP and CXR HDP were based on a 30-day rule, i.e. a new episode was considered if at least a 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.

<b>End point values</b>	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Consolidated pneumonia	2.181 (1.591 to 2.919)	3.965 (3.149 to 4.929)		
Non-consolidated pneumonia	2.908 (2.219 to 3.744)	2.937 (2.241 to 3.781)		
Consolidated or non-consolidated pneumonia	5.090 (4.163 to 6.161)	6.903 (5.810 to 8.141)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia with CXR reading according to WHO criteria - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia with CXR reading according to WHO criteria - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia [HDP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata for non-consolidated HDP and without strata for consolidated HDP). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. CXR HDP was defined as a HDP case with the presence of abnormal pulmonary infiltrates on the CXR as per independent review panel judgement using WHO methodology. Abnormal pulmonary infiltrates could be either with (Consolidated HDP) or without (Non-consolidated HDP) alveolar consolidation/pleural effusion. New cases of HDP and CXR HDP were based on a 30-day rule, i.e. a new episode was considered if at least a 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.

<b>End point values</b>	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Consolidated pneumonia	2.273 (1.658 to 3.042)	3.965 (3.149 to 4.929)		
Non-consolidated pneumonia	2.627 (1.962 to 3.445)	2.937 (2.241 to 3.781)		

Consolidated or non-consolidated pneumonia	4.901 (3.974 to 5.978)	6.903 (5.810 to 8.141)		
--	------------------------	------------------------	--	--

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia with CXR reading according to WHO criteria - In children starting vaccination in the 7-11 months schedule.

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia with CXR reading according to WHO criteria - In children starting vaccination in the 7-11 months schedule.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia [HDP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata for non-consolidated HDP and without strata for consolidated HDP). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. CXR HDP was defined as a HDP case with the presence of abnormal pulmonary infiltrates on the CXR as per independent review panel judgement using WHO methodology. Abnormal pulmonary infiltrates could be either with (Consolidated HDP) or without (Non-consolidated HDP) alveolar consolidation/pleural effusion. New cases of HDP and CXR HDP were based on a 30-day rule, i.e. a new episode was considered if at least a 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

End point values	10Pn7-11M/043+053 Group	Ctrl7-11M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3880	1907		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Consolidated pneumonia	1.960 (1.142 to 3.139)	4.401 (2.650 to 6.873)		
Non-consolidated pneumonia	3.344 (2.240 to 4.803)	4.865 (3.011 to 7.436)		
Consolidated or non-consolidated pneumonia	5.305 (3.884 to 7.076)	9.266 (6.620 to 12.618)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Person Year Rate in reducing hospital-diagnosed pneumonia with CXR reading according to WHO criteria - In children starting vaccination in the 12-18 months schedule.**

End point title	Person Year Rate in reducing hospital-diagnosed pneumonia with CXR reading according to WHO criteria - In children starting vaccination in the 12-18 months schedule.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with hospital-diagnosed pneumonia [HDP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata for non-consolidated HDP and without strata for consolidated HDP). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. CXR HDP was defined as a HDP case with the presence of abnormal pulmonary infiltrates on the CXR as per independent review panel judgement using WHO methodology. Abnormal pulmonary infiltrates could be either with (Consolidated HDP) or without (Non-consolidated HDP) alveolar consolidation/pleural effusion. New cases of HDP and CXR HDP were based on a 30-day rule, i.e. a new episode was considered if at least a 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

End point values	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6534	3126		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Consolidated pneumonia	1.824 (1.202 to 2.654)	3.494 (2.261 to 5.157)		
Non-consolidated pneumonia	2.837 (2.045 to 3.835)	2.935 (1.817 to 4.486)		
Consolidated or non-consolidated pneumonia	4.661 (3.626 to 5.899)	6.428 (4.706 to 8.574)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Person Year Rate in prevention of all tympanostomy tube placements- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.**

End point title	Person Year Rate in prevention of all tympanostomy tube placements- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with tympanostomy tube placement[TTP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. A TTP episode was defined as a TTP episode classified under the DCA 20 code in the Finnish National Institute of Health and Welfare (THL) and Social Insurance Institution of Finland (KELA) registers, using the Nordic Centre for

Classifications in Health Care (NOMESCO) Classification of Surgical Procedures (NCSP), version 1.12 from January 2008, and could refer to either an unilateral or a bilateral TTP procedure. New episodes of TTP defined according to a 30-day rule meaning that a new episode was considered if at least 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
End point timeframe:	
Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.	

<b>End point values</b>	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	68.735 (65.203 to 72.408)	79.504 (75.683 to 83.467)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in prevention of all tympanostomy tube placements - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.

End point title	Person Year Rate in prevention of all tympanostomy tube placements - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with tympanostomy tube placement[TTP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. A TTP episode was defined as a TTP episode classified under the DCA 20 code in the Finnish National Institute of Health and Welfare (THL) and Social Insurance Institution of Finland (KELA) registers, using the Nordic Centre for Classifications in Health Care (NOMESCO) Classification of Surgical Procedures (NCSP), version 1.12 from January 2008, and could refer to either an unilateral or a bilateral TTP procedure. New episodes of TTP defined according to a 30-day rule meaning that a new episode was considered if at least 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
End point timeframe:	
Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.	

<b>End point values</b>	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	66.083 (62.550 to 69.764)	79.504 (75.683 to 83.467)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in prevention of all tympanostomy tube placements - In children starting vaccination in the 7-11 months schedule.

End point title	Person Year Rate in prevention of all tympanostomy tube placements - In children starting vaccination in the 7-11 months schedule.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with tympanostomy tube placement[TTP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. A TTP episode was defined as a TTP episode classified under the DCA 20 code in the Finnish National Institute of Health and Welfare (THL) and Social Insurance Institution of Finland (KELA) registers, using the Nordic Centre for Classifications in Health Care (NOMESCO) Classification of Surgical Procedures (NCSP), version 1.12 from January 2008, and could refer to either an unilateral or a bilateral TTP procedure. New episodes of TTP defined according to a 30-day rule meaning that a new episode was considered if at least 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

<b>End point values</b>	10Pn7-11M/043+053 Group	Ctrl7-11M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3880	1907		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	68.153 (62.769 to 73.876)	79.920 (71.708 to 88.814)		

### Statistical analyses

No statistical analyses for this end point

**Secondary: Person Year Rate in prevention of all tympanostomy tube placements - In children starting vaccination in the 12-18 months schedule.**

End point title	Person Year Rate in prevention of all tympanostomy tube placements - In children starting vaccination in the 12-18 months schedule.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with tympanostomy tube placement [TTP]) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. A TTP episode was defined as a TTP episode classified under the DCA 20 code in the Finnish National Institute of Health and Welfare (THL) and Social Insurance Institution of Finland (KELA) registers, using the Nordic Centre for Classifications in Health Care (NOMESCO) Classification of Surgical Procedures (NCSP), version 1.12 from January 2008, and could refer to either an unilateral or a bilateral TTP procedure. New episodes of TTP defined according to a 30-day rule meaning that a new episode was considered if at least 30-day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

End point values	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6534	3126		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	56.809 (53.034 to 60.782)	58.973 (53.480 to 64.877)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Person Year Rate in prevention of all antimicrobial prescriptions- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.**

End point title	Person Year Rate in prevention of all antimicrobial prescriptions- In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with antimicrobial prescriptions (APs)) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. An APs episode was an episode of APs to an infant/child falling under following Anatomic Therapeutic Chemical [ATC] codes: J01 (APs) and following codes for AP usually recommended for otitis media (OM) and respiratory tract infections (RTI). "For OM and RTI" category corresponds to following definition: APs for antibacterial usually recommended for OM and RTI (ATC codes: J01CA04, J01CR02, J01CE02, J01DC02, J01DC04, J01EE02, J01FA09 and J01FA10). New episodes of APs were analyzed according to a 2-day rule meaning new episode considered if at least 2 day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.

End point values	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Antimicrobial prescriptions (ATC code J01)	1592.585 (1575.411 to 1609.901)	1706.194 (1688.328 to 1724.202)		
For otitis media and respiratory infections	1451.141 (1434.749 to 1467.674)	1565.692 (1548.579 to 1582.947)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in prevention of all antimicrobial prescriptions - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.

End point title	Person Year Rate in prevention of all antimicrobial prescriptions - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with antimicrobial prescriptions (APs)) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. An APs episode was an episode of APs to an infant/child falling under following Anatomic Therapeutic Chemical [ATC] codes: J01 (APs) and following codes for AP usually recommended for otitis media (OM) and respiratory tract infections (RTI). "For OM and RTI" category corresponds to following definition: APs for antibacterial usually recommended for OM and RTI (ATC codes: J01CA04, J01CR02, J01CE02, J01DC02, J01DC04, J01EE02, J01FA09 and J01FA10). New episodes of APs were analyzed according to a 2-day rule meaning new episode considered if at least 2 day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=24 months.

<b>End point values</b>	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10054	10200		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Antimicrobial prescriptions (ATC code J01)	1552.493 (1535.183 to 1569.950)	1706.194 (1688.328 to 1724.202)		
For otitis media and respiratory infections	1415.983 (1399.453 to 1432.659)	1565.692 (1548.579 to 1582.947)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in prevention of all antimicrobial prescriptions - In children starting vaccination in the 7-11 months schedule.

End point title	Person Year Rate in prevention of all antimicrobial prescriptions - In children starting vaccination in the 7-11 months schedule.
-----------------	---

End point description:

PYAR was calculated:  $n$  (= number of subjects with antimicrobial prescriptions (APs)) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. An APs episode was an episode of APs to an infant/child falling under following Anatomic Therapeutic Chemical [ATC] codes: J01 (APs) and following codes for AP usually recommended for otitis media (OM) and respiratory tract infections (RTI). "For OM and RTI" category corresponds to following definition: APs for antibacterial usually recommended for OM and RTI (ATC codes: J01CA04, J01CR02, J01CE02, J01DC02, J01DC04, J01EE02, J01FA09 and J01FA10). New episodes of APs were analyzed according to a 2-day rule meaning new episode considered if at least 2 day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) - FU mean time=27 months.

<b>End point values</b>	10Pn7-11M/043+053 Group	Ctrl7-11M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3880	1907		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Antimicrobial prescriptions (ATC code J01)	1536.618 (1510.637 to 1562.934)	1649.360 (1611.269 to 1688.124)		
For otitis media and respiratory infections	1390.856 (1366.143 to 1415.903)	1499.713 (1463.401 to 1536.698)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Person Year Rate in prevention of all antimicrobial prescriptions - In children starting vaccination in the 12-18 months schedule.

End point title	Person Year Rate in prevention of all antimicrobial prescriptions - In children starting vaccination in the 12-18 months schedule.
-----------------	--

End point description:

PYAR was calculated:  $n$  (= number of subjects with antimicrobial prescriptions (APs)) divided by  $T$  (= sum of follow-up (FU) period expressed in years) (per 1000) with 95% CI (2-sided profile log-likelihood ratio 95% CI-classical log linear Poisson regression with strata). FU period considered as period between Dose 1 administration and cut-off date of 31 December 2011. An APs episode was an episode of APs to an infant/child falling under following Anatomic Therapeutic Chemical [ATC] codes: J01 (APs) and following codes for AP usually recommended for otitis media (OM) and respiratory tract infections (RTI). "For OM and RTI" category corresponds to following definition: APs for antibacterial usually recommended for OM and RTI (ATC codes: J01CA04, J01CR02, J01CE02, J01DC02, J01DC04, J01EE02, J01FA09 and J01FA10). New episodes of APs were analyzed according to a 2-day rule meaning new episode considered if at least 2 day interval elapsed from the onset of the previous episode.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – FU mean time=27 months.

End point values	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6534	3126		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Antimicrobial prescriptions (ATC code J01)	1315.936 (1297.521 to 1334.547)	1421.774 (1394.280 to 1449.675)		
For otitis media and respiratory infections	1177.729 (1160.312 to 1195.343)	1271.268 (1245.277 to 1297.665)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects classified by antimicrobial susceptibility of IPD isolates in children starting vaccination within 7 months of life and assigned to a 2

### or 3-dose primary vaccination course

End point title	Number of subjects classified by antimicrobial susceptibility of IPD isolates in children starting vaccination within 7 months of life and assigned to a 2 or 3-dose primary vaccination course
-----------------	---

End point description:

Antimicrobial susceptibility classification of IPD isolates reported during IPD follow-up with percentages for each serotype for the following categories: S= susceptible; I = intermediate ; R = resistant; N = not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end date of the follow-up (31 December 2011) – mean FU time=24 months.

End point values	10Pn3+1-6W-6M/043+053 Group	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	0 <sup>[5]</sup>	2	24	
Units: Participants				
Serotype-4 -Pencillin-S		0	1	
Serotype-6A -Pencillin-S		0	1	
Serotype-6B -Pencillin-I		0	3	
Serotype-6B -Pencillin-R		0	1	
Serotype-6B -Pencillin-S		0	2	
Serotype-7F -Pencillin-S		1	1	
Serotype-14 -Pencillin-I		0	2	
Serotype-14 -Pencillin-R		0	1	
Serotype-14 -Pencillin-S		0	2	
Serotype-15C -Pencillin-S		0	1	
Serotype-18C -Pencillin-S		0	1	
Serotype-19A -Pencillin-I		0	1	
Serotype-19F -Pencillin-I		0	1	
Serotype-19F -Pencillin-S		0	1	
Serotype-23F -Pencillin-S		0	1	
Serotype-N -Pencillin-N		1	4	
Serotype-4 -Erythromycin-S		0	1	
Serotype-6A -Erythromycin-S		0	1	
Serotype-6B -Erythromycin-R		0	5	
Serotype-6B -Erythromycin-S		0	1	
Serotype-7F -Erythromycin-S		1	1	
Serotype-14 -Erythromycin-R		0	4	
Serotype-14 -Erythromycin-S		0	1	
Serotype-15C -Erythromycin-S		0	1	
Serotype-18C -Erythromycin-S		0	1	
Serotype-19A -Erythromycin-S		0	1	
Serotype-19F -Erythromycin-R		0	1	
Serotype-19F -Erythromycin-S		0	1	
Serotype-23F -Erythromycin-S		0	1	
Serotype-N -Erythromycin-N		1	4	
Serotype-4 -Tetracyclin-S		0	1	
Serotype-6A -Tetracyclin-S		0	1	

Serotype-6B -Tetracyclin-R	0	4
Serotype-6B -Tetracyclin-S	0	2
Serotype-7F -Tetracyclin-S	1	1
Serotype-14 -Tetracyclin-S	0	5
Serotype-15C -Tetracyclin-S	0	1
Serotype-18C -Tetracyclin-S	0	1
Serotype-19A -Tetracyclin-S	0	1
Serotype-19F -Tetracyclin-R	0	1
Serotype-19F -Tetracyclin-S	0	1
Serotype-23F -Tetracyclin-S	0	1
Serotype-N -Tetracyclin-N	1	4
Serotype-4 -Levofloxacin-S	0	1
Serotype-6A -Levofloxacin-S	0	1
Serotype-6B -Levofloxacin-S	0	6
Serotype-7F -Levofloxacin-S	1	1
Serotype-14 -Levofloxacin-S	0	5
Serotype-15C -Levofloxacin-S	0	1
Serotype-18C -Levofloxacin-S	0	1
Serotype-19A -Levofloxacin-S	0	1
Serotype-19F -Levofloxacin-S	0	2
Serotype-23F -Levofloxacin-S	0	1
Serotype-N -Levofloxacin-N	1	4
Serotype-4 -Ceftriaxone-S	0	1
Serotype-6A -Ceftriaxone-S	0	1
Serotype-6B -Ceftriaxone-S	0	6
Serotype-7F -Ceftriaxone-S	1	1
Serotype-14 -Ceftriaxone-I	0	1
Serotype-14 -Ceftriaxone-S	0	4
Serotype-15C -Ceftriaxone-S	0	1
Serotype-18C -Ceftriaxone-S	0	1
Serotype-19A -Ceftriaxone-S	0	1
Serotype-19F -Ceftriaxone-S	0	2
Serotype-23F -Ceftriaxone-S	0	1
Serotype-N -Ceftriaxone-N	1	4
Serotype-4 -Clindamycin-S	0	1
Serotype-6A -Clindamycin-S	0	1
Serotype-6B -Clindamycin-R	0	4
Serotype-6B -Clindamycin-S	0	2
Serotype-7F -Clindamycin-S	1	1
Serotype-14 -Clindamycin-N	0	1
Serotype-14 -Clindamycin-S	0	4
Serotype-15C -Clindamycin-S	0	1
Serotype-18C -Clindamycin-S	0	1
Serotype-19A -Clindamycin-S	0	1
Serotype-19F -Clindamycin-R	0	1
Serotype-19F -Clindamycin-S	0	1
Serotype-23F -Clindamycin-S	0	1
Serotype-N -Clindamycin-N	1	4

Notes:

[5] - No data collected for this group

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with Lower respiratory tract infections (LRTIs) (in a subset of subjects in Turku area )

End point title	Number of subjects with Lower respiratory tract infections (LRTIs) (in a subset of subjects in Turku area )
-----------------	---

End point description:

Analysis of this outcome was performed in the Turku area. The number of subjects reporting at least one LRTI any time after the administration of the first vaccine dose was tabulated. The analysis was performed in a subset of vaccinated subjects including all vaccinated subjects enrolled in the 10PNPD-DIT-053 study in the Turku area and those vaccinated subjects enrolled in the 10PN-PD-DIT-043 study in the Turku area who agreed to take part in this assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

From the administration of the first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (at least 30 months)

End point values	10Pn3+1-6W-6M/043+053 Group	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group	10Pn7-11M/043+053 Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	243	190	171	31
Units: Participants	19	19	19	3

End point values	Ctrl7-11M/043+053 Group	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	22	62	48	
Units: Participants	1	5	2	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with Upper respiratory tract infections (URTIs) (in a subset of subjects in Turku area)

End point title	Number of subjects with Upper respiratory tract infections (URTIs) (in a subset of subjects in Turku area)
-----------------	--

End point description:

Analysis of this outcome was performed in the Turku area. The number of subjects reporting at least one URTI any time after the administration of the first vaccine dose was tabulated. The analysis was performed in a subset of vaccinated subjects including all vaccinated subjects enrolled in the 10PNPD-DIT-053 study in the Turku area and those vaccinated subjects enrolled in the 10PN-PD-DIT-043 study in the Turku area who agreed to take part in this assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

From the administration of the first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (at least 30 months)

End point values	10Pn3+1-6W-6M/043+053 Group	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group	10Pn7-11M/043+053 Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	243	190	171	31
Units: Participants	158	124	94	14

End point values	Ctrl7-11M/043+053 Group	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	22	62	48	
Units: Participants	15	27	19	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with any and Grade 3 solicited local symptoms.

End point title	Number of subjects with any and Grade 3 solicited local symptoms.
-----------------	---

End point description:

Assessed solicited local symptoms were pain (P), redness (R) and swelling (S). Any = occurrence of the symptom regardless of intensity grade. Grade 3 (G3) pain = cried when limb was moved/spontaneously painful. G3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 4 days (4D) after each vaccination (M0+4D, M1+4D [only for 3+1 schedule], M2+4D, M8+4D [booster dose] for 6W-6M subjects; M0+4D, M2+4D, M6+4D [booster dose] for 7M-11M subjects; M0+4D, M6+4D for 12M-18M subjects)

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1846	1302	1066	852
Units: Participants				
Any P, D1 (N=1846,1302,1066,852,237,202,363,2)	807	611	146	106
G3 P, D1 (N=1846,1302,1066,852,237,202,363,270)	60	43	2	3

Any R, D1(N=1846,1302,1066,852,237,202,36	936	675	270	214
G3 R, D1 (N=1846,1302,1066,852,237,202,363,2	56	48	3	0
Any S, D1(N=1846,1302,1066,852,237,202,36	636	471	88	64
G3 S, D1(N=1846,1302,1066,852,237,202,36	89	69	4	1
Any P, D2 (N=1827,1287,1056,847,229,199,345,2	662	509	114	94
G3 P, D2 (N=1827,1287,1056,847,229,199,345,2	23	28	2	1
Any R, D2(N=1827,1287,1056,847,229,199,34	996	690	254	203
G3 R, D2 (N=1827,1287,1056,847,229,199,345,2	48	63	3	0
Any S, D2(N=1827,1287,1056,847,229,199,34	686	536	114	79
G3 S, D2 (N=1827,1287,1056,847,229,199,345,2	67	91	4	1
Any P, D3 (N=1808,0,1052,0,0,0,0,0)	538	0	102	0
G3 P, D3 (N=1808,0,1052,0,0,0,0,0)	12	0	2	0
Any R D3 (N=1808,0,1052,0,0,0,0,0)	963	0	300	0
G3 R, D3 (N=1808,0,1052,0,0,0,0,0)	52	0	0	0
Any S, D3 (N=1808,0,1052,0,0,0,0,0)	676	0	144	0
G3 S, D3 (N=1808,0,1052,0,0,0,0,0)	62	0	1	0
Any P, B dose (N=1758,1258,1024,827,216,188,0,0)	888	710	250	171
G3 P, B dose (N=1758,1258,1024,827,216,188,0,0)	66	41	2	2
Any R, B dose(N=1758,1258,1024,827,216,188,0	913	702	345	238
G3 R, B dose (N=1758,1258,1024,827,216,188,0,0)	102	103	13	2
Any S, B dose(N=1758,1258,1024,827,216,188,0	716	586	229	118
G3 S, B dose (N=1758,1258,1024,827,216,188,0,0)	102	111	10	3

End point values	10Pn7- 11M/053 Group	Ctrl7-11M/053 Group	10Pn12- 18M/053 Group	Ctrl12- 18M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	237	202	363	270
Units: Participants				
Any P, D1 (N=1846,1302,1066,852,237,202,363,2	120	33	220	65
G3 P, D1 (N=1846,1302,1066,852,237, 202,363,270)	6	0	19	0
Any R, D1(N=1846,1302,1066,852,237,202,36	137	48	203	93
G3 R, D1 (N=1846,1302,1066,852,237,202,363,2	17	0	39	0
Any S, D1(N=1846,1302,1066,852,237,202,36	107	19	142	25
G3 S, D1(N=1846,1302,1066,852,237,202,36	20	9	35	1

Any P, D2 (N=1827,1287,1056,847,229,199,345,2	108	38	242	78
G3 P, D2 (N=1827,1287,1056,847,229,199,345,2	11	0	45	0
Any R, D2(N=1827,1287,1056,847,229,199,34	124	57	193	85
G3 R, D2 (N=1827,1287,1056,847,229,199,345,2	21	0	49	1
Any S, D2(N=1827,1287,1056,847,229,199,34	98	18	148	26
G3 S, D2 (N=1827,1287,1056,847,229,199,345,2	19	0	34	0
Any P, D3 (N=1808,0,1052,0,0,0,0,0)	0	0	0	0
G3 P, D3 (N=1808,0,1052,0,0,0,0,0)	0	0	0	0
Any R D3 (N=1808,0,1052,0,0,0,0,0)	0	0	0	0
G3 R, D3 (N=1808,0,1052,0,0,0,0,0)	0	0	0	0
Any S, D3 (N=1808,0,1052,0,0,0,0,0)	0	0	0	0
G3 S, D3 (N=1808,0,1052,0,0,0,0,0)	0	0	0	0
Any P, B dose (N=1758,1258,1024,827,216,188,0,0)	123	40	0	0
G3 P, B dose (N=1758,1258,1024,827,216,188,0,0)	14	2	0	0
Any R, B dose(N=1758,1258,1024,827,216,188,0	106	54	0	0
G3 R, B dose (N=1758,1258,1024,827,216,188,0,0)	18	0	0	0
Any S, B dose(N=1758,1258,1024,827,216,188,0	85	31	0	0
G3 S, B dose (N=1758,1258,1024,827,216,188,0,0)	14	0	0	0

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with any, Grade 3 and related solicited general symptoms.

End point title	Number of subjects with any, Grade 3 and related solicited general symptoms.
-----------------	--

End point description:

Assessed solicited general symptoms were drowsiness (D), fever [defined as rectal temperature [T(R)]  $\geq 38$  degrees Celsius ( $^{\circ}$ C) or oral/axillary/tympanic temperature equal to or above  $37.5^{\circ}$ C], irritability/fussiness (I) and loss of appetite (L ap). Any = occurrence of the symptom regardless of intensity grade. Grade 3 (G3) drowsiness = drowsiness that prevented normal activity. G3 fever = rectal temperature  $> 40^{\circ}$ C. G3 irritability/fussiness = cried that could not be comforted/prevented normal activity. G3 loss of appetite = not eating at all. Related (Rel) = a symptom assessed by investigator as causally related to the vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 4 days (4D) after each vaccination (M0+4D, M1+4D [only for 3+1 schedule], M2+4D, M8+4D [booster dose] for 6W-6M subjects; M0+4D, M2+4D, M6+4D [booster dose] for 7M-11M subjects; M0+4D, M6+4D for 12M-18M subjects)

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1846	1302	1066	852
Units: Participants				
Any D, D1 (N=1846,1302,1066,852,237,202,363,2	1070	742	462	384
G3 D, D1 (N=1846,1302,1066,852,237,202,363,2	11	8	5	1
Rel D, D1 (N=1846,1302,1066,852,237,202,363,2	1054	738	453	374
Any T (R),D1(N=1846,1302,1066,852,237,202	388	289	82	78
G3 T(R), D1 (N=1846,1302,1066,852,237,202,363,2	2	0	1	0
Rel T(R),D1 (N=1846,1302,1066,852,237,202,363,2	381	284	78	74
Any I, D1 (N=1846,1302,1066,852,237,202,363,2	1325	942	577	468
G3 I, D1 (N=1846,1302,1066,852,237,202,363,2	76	56	20	14
Rel I, D1 (N=1846,1302,1066,852,237,202,363,2	1298	937	565	460
Any L.ap,D1 (N=1846,1302,1066,852,237,202,363,2	499	335	202	147
G3 L.ap, D1 (N=1846,1302,1066,852,237,202,363,2	1	3	2	0
Rel L.ap,D1 (N=1846,1302,1066,852,237,202,363,2	480	332	196	140
Any D, D2 (N=1828,1287,1056,847,229,198,345,2	868	572	332	258
G3 D, D2 (N=1828,1287,1056,847,229,198,345,2	7	6	1	3
Rel D, D2 (N=1828,1287,1056,847,229,198,345,2	855	564	329	247
Any T(R), D2(N=1828,1287,1056,847,229,198,34	380	382	78	80
G3 T(R), D2 (N=1828,1287,1056,847,229,198,345,2	2	0	0	0
Rel T(R), D2(N=1828,1287,1056,847,229,198,34	373	378	78	71
Any I, D2 (N=1828,1287,1056,847,229,198,345,2	1254	822	532	408
G3 I, D2 (N=1828,1287,1056,847,229,198,345,2	73	44	13	14
Rel I, D2 (N=1828,1287,1056,847,229,198,345,2	1236	816	523	396
Any L.ap, D2(N=1828,1287,1056,847,229,198,34	434	323	187	149
G3 L.ap, D2 (N=1828,1287,1056,847,229,198,345,2	4	2	1	3
Rel L.ap, D2(N=1828,1287,1056,847,229,198,34	419	318	181	135
Any D, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	645	0	293	0
G3 D, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	2	0	2	0
Rel D, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	638	0	285	0
Any T (R), D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	347	0	110	0

G3 T (R), D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	1	0	1	0
Rel T (R), D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	336	0	106	0
Any I, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	1115	0	496	0
G3 I, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	41	0	14	0
Rel I, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	1100	0	492	0
Any L.ap, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	349	0	178	0
G3 L.ap, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	3	0	0	0
Rel L.ap, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	336	0	172	0
Any D, B dose (N=1757,1257,1024,827,216,188,0,0)	721	561	307	243
G3 D, B dose (N=1757,1257,1024,827,216,188,0,0)	8	8	3	4
Rel D, B dose (N=1757,1257,1024,827,216,188,0,0)	699	548	300	233
Any T(R), B dose(N=1757,1257,1024,827,216,188,0,0)	391	333	142	120
G3 T(R), B dose(N=1757,1257,1024,827,216,188,0,0)	3	0	0	1
Rel T(R), B dose(N=1757,1257,1024,827,216,188,0,0)	371	319	134	110
Any I, B dose (N=1757,1257,1024,827,216,188,0,0)	1124	816	491	410
G3 I, B dose (N=1757,1257,1024,827,216,188,0,0)	47	33	14	7
Rel I, B dose (N=1757,1257,1024,827,216,188,0,0)	1085	801	481	395
Any L.ap, B dose(N=1757,1257,1024,827,216,188,0,0)	549	411	260	186
G3 L.ap, B dose(N=1757,1257,1024,827,216,188,0,0)	12	5	6	3
Rel L.ap, B dose(N=1757,1257,1024,827,216,188,0,0)	513	398	253	173

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group	10Pn12-18M/053 Group	Ctrl12-18M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	237	202	363	270
Units: Participants				
Any D, D1 (N=1846,1302,1066,852,237,202,363,2)	106	62	155	87
G3 D, D1 (N=1846,1302,1066,852,237,202,363,2)	1	0	1	2
Rel D, D1 (N=1846,1302,1066,852,237,202,363,2)	103	57	152	81
Any T (R),D1(N=1846,1302,1066,852,237,202)	38	16	74	28
G3 T(R), D1 (N=1846,1302,1066,852,237,202,363,2)	8	0	2	2

Rel T(R),D1 (N=1846,1302,1066,852,237,202,363,2	35	13	69	25
Any I, D1 (N=1846,1302,1066,852,237,202,363,2	157	90	210	103
G3 I, D1 (N=1846,1302,1066,852,237,202,363,2	3	2	6	4
Rel I, D1 (N=1846,1302,1066,852,237,202,363,2	157	83	201	96
Any L.ap,D1 (N=1846,1302,1066,852,237,202,363,2	84	56	128	82
G3 L.ap, D1 (N=1846,1302,1066,852,237,202,363,2	0	1	2	4
Rel L.ap,D1 (N=1846,1302,1066,852,237,202,363,2	81	48	123	73
Any D, D2 (N=1828,1287,1056,847,229,198,345,2	88	52	126	58
G3 D, D2 (N=1828,1287,1056,847,229,198,345,2	2	1	2	1
Rel D, D2 (N=1828,1287,1056,847,229,198,345,2	85	51	123	55
Any T(R), D2(N=1828,1287,1056,847,229,198,34	44	20	55	11
G3 T(R), D2 (N=1828,1287,1056,847,229,198,345,2	0	1	2	1
Rel T(R), D2(N=1828,1287,1056,847,229,198,34	43	15	53	8
Any I, D2 (N=1828,1287,1056,847,229,198,345,2	139	94	193	72
G3 I, D2 (N=1828,1287,1056,847,229,198,345,2	7	1	3	0
Rel I, D2 (N=1828,1287,1056,847,229,198,345,2	137	93	191	71
Any L.ap, D2(N=1828,1287,1056,847,229,198,34	69	56	109	57
G3 L.ap, D2 (N=1828,1287,1056,847,229,198,345,2	44	0	2	1
Rel L.ap, D2(N=1828,1287,1056,847,229,198,34	0	52	105	54
Any D, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
G3 D, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Rel D, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Any T (R), D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
G3 T (R), D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Rel T (R), D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Any I, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
G3 I, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Rel I, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Any L.ap, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
G3 L.ap, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0
Rel L.ap, D3 (N=1808, 0, 1052, 0, 0, 0, 0, 0)	0	0	0	0

Any D, B dose (N=1757,1257,1024,827,216,188,0,0)	92	47	0	0
G3 D, B dose (N=1757,1257,1024,827,216,188,0,0)	2	1	0	0
Rel D, B dose (N=1757,1257,1024,827,216,188,0,0)	87	46	0	0
Any T(R), B dose(N=1757,1257,1024,827,216,188,0	42	11	0	0
G3 T(R), B dose(N=1757,1257,1024,827,216,188,0	1	0	0	0
Rel T(R), B dose(N=1757,1257,1024,827,216,188,0	41	8	0	0
Any I, B dose (N=1757,1257,1024,827,216,188,0,0)	129	84	0	0
G3 I, B dose (N=1757,1257,1024,827,216,188,0,0)	2	1	0	0
Rel I, B dose (N=1757,1257,1024,827,216,188,0,0)	124	80	0	0
Any L.ap, B dose(N=1757,1257,1024,827,216,188,0	64	46	0	0
G3 L.ap, B dose(N=1757,1257,1024,827,216,188,0	2	1	0	0
Rel L.ap, B dose(N=1757,1257,1024,827,216,188,0	60	43	0	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with any unsolicited adverse events (AEs).

End point title	Number of subjects with any unsolicited adverse events (AEs).
-----------------	---

End point description:

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 31 days (31D) after each vaccination (M0+31D, M1+31D [only for 3+1 schedule], M2+31D, M8+31D [booster dose] for 6W-6M subjects; M0+31D, M2+31D, M6+31D [booster dose] for 7M-11M subjects; M0+31D, M6+31D for 12M-18M subjects)

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1849	1316	1069	859
Units: Participants				
Un AEs, Pr. (N=1849,1316,1069,859,241,204,368,2	1105	598	554	337
Un AEs, Booster (N=1786,1275,1043,837,226,197,0,0)	521	363	277	244

<b>End point values</b>	10Pn7-11M/053 Group	Ctrl7-11M/053 Group	10Pn12-18M/053 Group	Ctrl12-18M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	241	204	368	271
Units: Participants				
Un AEs, Pr. (N=1849,1316,1069,859,241,204,368,271)	157	132	221	174
Un AEs, Booster (N=1786,1275,1043,837,226,197,0,0)	51	48	0	0

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with serious adverse events (SAEs).

End point title	Number of subjects with serious adverse events (SAEs).
-----------------	--

End point description:

An event is defined as 'serious' when it meets one of the pre-defined outcomes described below: results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation; results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious.

End point type	Secondary
----------------	-----------

End point timeframe:

Following administration of the first vaccine dose up to study end (M0 up to M18 for subjects aged 6W to 6M at enrollment; M0 up to M16 for subjects aged 7M to 11M at enrollment; M0 up to M9 for subjects aged 12M to 18M at enrollment)

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1849	1316	1069	859
Units: Participants	163	96	77	74

<b>End point values</b>	10Pn7-11M/053 Group	Ctrl7-11M/053 Group	10Pn12-18M/053 Group	Ctrl12-18M/053 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	241	204	368	271
Units: Participants	24	18	23	14

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects enrolled and vaccinated in the 10PN-PD-DIT-043 and 10PN-PD-DIT-053 study with post-study SAEs reported via passive surveillance– Subjects enrolled aged 6 weeks to 6 months and 7 to 18 months

End point title	Number of subjects enrolled and vaccinated in the 10PN-PD-DIT-043 and 10PN-PD-DIT-053 study with post-study SAEs reported via passive surveillance– Subjects enrolled aged 6 weeks to 6 months and 7 to 18 months
-----------------	---

#### End point description:

An event is defined as 'serious' when it meets one of the pre-defined outcomes described below: results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation; results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious.

End point type	Secondary
----------------	-----------

#### End point timeframe:

From the end of the blinded ID Follow-Up period (at least 30 months from the study start) up to the end of 18-month period after study unblinding

End point values	10Pn3+1-6W-6M/043+053 Group	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group	10Pn7-11M/043+053 Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10273	10054	10201	3880
Units: Participants	1	2	0	0

End point values	Ctrl7-11M/043+053 Group	10Pn12-18M/043+053 Group	Ctrl12-18M/043+053 Group	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	1908	6535	3126	
Units: Participants	0	0	0	

## Statistical analyses

No statistical analyses for this end point

**Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE PATHOGENS (S. PN.), ANY PATHOGEN. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN**

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE PATHOGENS (S. PN.), ANY PATHOGEN. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[6]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. The "prior to dose 1" nasopharyngeal swab samples collected from subjects within their first 7 months of age were obtained solely from the Immuno subset (The Immuno subset was constituted of the first +/- 1500 subjects from whom blood samples were collected, according to age and treatment groups).

End point type	Secondary
----------------	-----------

End point timeframe:

At 3 months (mths) of age (prior to dose 1); at 6 mths of age (1 mth post dose 3 or post dose 2); at 11-12 mths of age (pre-booster dose); at 14-15 mths of age (3 mths post-booster); at 18-22 mths of age (10 mths post-booster)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1803	1289	1897	
Units: swab samples				
3 Months (N=253,253,341)	49	31	56	
6 Months (N=1803,1289,1897)	412	323	464	
11-12 Months (N=1784,1269,1877)	500	383	604	
14-15 Months (N=1727, 1227, 1814)	512	370	638	
18-22 Months (N=1686, 1216, 1769)	503	430	736	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE PATHOGENS (S. PN.), ANY PATHOGEN. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE PATHOGENS (S. PN.), ANY PATHOGEN. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[7]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 7-11 months (mths) of age (prior to dose 1); at 9-13 mths of age (1 mth post dose 2); at 13-17 mths of age (pre-booster dose); at 16-20 mths of age (3 mths post-booster); at 23-27 mths of age (10

## Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

<b>End point values</b>	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	200		
Units: swab samples				
7-11 Months (N=236, 198)	69	58		
9-13 Months (N=230, 200)	79	56		
13-17 Months (N= 225, 197)	81	87		
16-20 Months (N= 209, 179)	75	72		
23-27 Months (N= 200, 175)	68	75		

### Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE PATHOGENS (S. PN.), ANY PATHOGEN. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE PATHOGENS (S. PN.), ANY PATHOGEN. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[8]</sup>
-----------------	---

#### End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

#### End point timeframe:

At 12-18 months (mths) of age (prior to dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

#### Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	265		
Units: swab samples				
12-18 Months (N= 358, 265)	125	88		
19-25 Months (N= 340, 255)	152	112		
21-27 Months (N= 338, 254)	132	105		

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPES. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPES. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[9]</sup>
-----------------	--

#### End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. The "prior to dose 1" nasopharyngeal swab samples collected from subjects within their first 7 months of age were obtained solely from the Immuno subset (The Immuno subset was constituted of the first ± 1500 subjects from whom blood samples were collected, according to age and treatment groups).

End point type	Secondary
----------------	-----------

#### End point timeframe:

At 3 months (mths) of age (prior to dose 1); at 6 mths of age (1 mth post dose 3 or post dose 2); at 11-12 mths of age (pre-booster dose); at 14-15 mths of age (3 mths post-booster); at 18-22 mths of age (10 mths post-booster)

#### Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1803	1289	1897	
Units: swab samples				
3 Months (N=253, 253, 341)	29	18	30	
6 Months (N= 1803, 1289, 1897)	183	159	237	
11-12 Months (N=1784, 1269, 1877)	229	178	342	
14-15 Months (N= 1727, 1227, 1814)	209	153	364	
18-22 Months (N=1686, 1216, 1769)	169	176	404	

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPES. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPES.
-----------------	--

## End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 7-11 months (mths) of age (prior to dose 1); at 9-13 mths of age (1 mth post dose 2); at 13-17 mths of age (pre-booster dose); at 16-20 mths of age (3 mths post-booster); at 23-27 mths of age (10 mths post-booster)

## Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	200		
Units: swab samples				
7-11 Months (N= 236, 198)	44	34		
9-13 Months (N= 230, 200)	43	35		
13-17 Months (N= 225, 197)	43	55		
16-20 Months (N= 209, 179)	34	47		
23-27 Months (N= 200, 175)	28	48		

### Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPES. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPES. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[11]</sup>
-----------------	--

## End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 12-18 months (mths) of age (prior to dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

## Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	265		
Units: swab samples				
12-18 Months (N= 358, 265)	70	57		
19-25 Months (N= 340, 255)	69	70		
21-27 Months (N= 338, 254)	64	53		

## Statistical analyses

No statistical analyses for this end point

### **Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) STRAINS, ANY PATHOGEN, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN**

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) STRAINS, ANY PATHOGEN, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[12]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 11-12 mths of age (pre-booster dose); at 14-15 mths of age (3 mths post-booster); at 18-22 mths of age (10 mths post-booster)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1780	1269	1874	
Units: Participants				
11-12 Months (N= 1780, 1269, 1874)	331	246	415	
14-15 Months (N= 1723, 1222, 1807)	562	400	692	
18-22 Months (N= 1675, 1200, 1752)	818	609	1023	

## Statistical analyses

No statistical analyses for this end point

### **Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) STRAINS, ANY PATHOGEN, IDENTIFIED IN**

**NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) STRAINS, ANY PATHOGEN, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[13]</sup>
-----------------	--

## End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 9-13 mths of age (1 mth post dose 2); at 13-17 mths of age (pre-booster dose); at 16-20 mths of age (3 mths post-booster); at 23-27 mths of age (10 mths post-booster)

## Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	226	195		
Units: Participants				
9-13 Months (N= 226, 195)	36	30		
13-17 Months (N= 221, 192)	78	83		
16-20 Months (N= 205, 175)	95	100		
23-27 Months (N= 194, 170)	117	116		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) STRAINS, ANY PATHOGEN, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) STRAINS, ANY PATHOGEN, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[14]</sup>
-----------------	---

## End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

## Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	249		
Units: Participants				
19-25 Months (N= 333, 249)	130	94		
21-27 Months (N= 330, 246)	166	133		

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPE STRAINS, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPE STRAINS, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[15]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 11-12 mths of age (pre-booster dose); at 14-15 mths of age (3 mths post-booster); at 18-22 mths of age (10 mths post-booster)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1780	1269	1874	
Units: Participants				
11-12 Months (N= 1780, 1269, 1874)	131	97	223	
14-15 Months (N= 1723, 1222, 1807)	221	156	387	
18-22 Months (N= 1675, 1200, 1752)	326	269	626	

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPE STRAINS, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPE STRAINS, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[16]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 9-13 mths of age (1 mth post dose 2); at 13-17 mths of age (pre-booster dose); at 16-20 mths of age (3 mths post-booster); at 23-27 mths of age (10 mths post-booster)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	226	195		
Units: Participants				
9-13 Months (N= 226, 195)	18	17		
13-17 Months (N= 221, 192)	41	51		
16-20 Months (N= 205, 175)	50	70		
23-27 Months (N= 194, 170)	62	88		

## Statistical analyses

No statistical analyses for this end point

### **Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPE STRAINS, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW STREPTOCOCCUS PNEUMONIAE (S. PN.) VACCINE SEROTYPE STRAINS, IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[17]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	249		
Units: Participants				
19-25 Months (N= 333, 249)	53	55		
21-27 Months (N= 330, 246)	78	74		

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[18]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. The "prior to dose 1" nasopharyngeal swab samples collected from subjects within their first 7 months of age were obtained solely from the Immuno subset (The Immuno subset was constituted of the first ± 1500 subjects from whom blood samples were collected, according to age and treatment groups). Data presented only include results from samples confirmed as positive for Hi/NTHi after differentiation from H. haemolyticus by PCR assay.

End point type	Secondary
----------------	-----------

End point timeframe:

At 3 months (mths) of age (prior to dose 1); at 6 mths of age (1 mth post dose 3 or post dose 2); at 11-12 mths of age (pre-booster dose); at 14-15 mths of age (3 mths post-booster); at 18-22 mths of age (10 mths post-booster)

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1803	1289	1897	
Units: Swab samples				
3 Months (N= 253, 253, 341)	6	4	10	
6 Months (N= 1803, 1289, 1897)	57	36	46	
11-12 Months (N= 1784, 1269, 1877)	84	72	87	
14-15 Months (N= 1726, 1227, 1814)	121	84	92	
18-22 Months (N= 1684, 1212, 1768)	211	128	190	

## Statistical analyses

No statistical analyses for this end point

**Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[19]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. Data presented only include results from samples confirmed as positive for Hi /NTHi after differentiation from H. haemolyticus by PCR assay.

End point type	Secondary
----------------	-----------

End point timeframe:

At 7-11 months (mths) of age (prior to dose 1); at 9-13 mths of age (1 mth post dose 2); at 13-17 mths of age (pre-booster dose); at 16-20 mths of age (3 mths post-booster); at 23-27 mths of age (10 mths post-booster)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	200		
Units: Swab samples				
7-11 Months (N= 236, 198)	6	8		
9-13 Months (N= 230, 200)	8	9		
13-17 Months (N= 225, 197)	22	14		
16-20 Months (N= 209, 179)	17	13		
23-27 Months (N= 200, 175)	21	15		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[20]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. Data presented only include results from samples confirmed as positive for Hi/NTHi after differentiation from H. haemolyticus by PCR assay.

End point type	Secondary
----------------	-----------

End point timeframe:

At 12-18 months (mths) of age (prior to dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	265		
Units: Swab samples				
12-18 Months (N= 358, 265)	21	12		
19-25 Months (N= 340, 255)	24	21		
21-27 Months (N= 338, 254)	27	29		

## Statistical analyses

No statistical analyses for this end point

## Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[21]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated. Data presented only include results from samples confirmed as positive for Hi/NTHi after differentiation from H. haemolyticus by PCR assay.

End point type	Secondary
----------------	-----------

End point timeframe:

At 11-12 mths of age (pre-booster dose) ; at 14-15 mths of age ( 3 mths post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1780	1269	1874	
Units: Participants				
11-12 Months (N= 1780, 1269, 1874)	77	65	83	
14-15 Months (N= 1722, 1222, 1807)	176	139	157	
18-22 Months (N= 1672, 1196, 1751)	349	240	313	

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[22]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated. Data presented only include results from samples confirmed as positive for Hi/NTHi after differentiation from H. haemolyticus by PCR assay.

End point type	Secondary
----------------	-----------

End point timeframe:

At 9-13 mths of age (1 mth post dose 2); at 13-17 mths of age (pre-booster dose); at 16-20 mths of age (3 mths post-booster) at 23-27 mths of age (10 mths post-booster)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	226	195		
Units: Participants				
9-13 Months (N= 226, 195)	8	9		
13-17 Months (N= 221, 192)	29	19		
16-20 Months (N= 205, 175)	37	28		
23-27 Months (N= 194, 170)	55	39		

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF SUBJECTS WITH ACQUISITION OF NEW HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN

End point title	NUMBER OF SUBJECTS WITH ACQUISITION OF NEW HAEMOPHILUS INFLUENZAE (H. INFL.) PATHOGENS IDENTIFIED IN NASOPHARYNGEAL SWABS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[23]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of subjects with new acquisition associated to the specified bacteria at the considered time point was tabulated. Data presented only include results from samples confirmed as positive for Hi/NTHi after differentiation from H. haemolyticus by PCR assay.

End point type	Secondary
----------------	-----------

End point timeframe:

At 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	249		
Units: Participants				
19-25 Months (N= 333, 249)	19	20		
21-27 Months (N= 330, 246)	37	41		

### Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH MORAXELLA CATARRHALIS PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH MORAXELLA CATARRHALIS PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[24]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. The "prior to dose 1" nasopharyngeal swab samples collected from subjects within their first 7 months of age were obtained solely from the Immuno subset (The Immuno subset was constituted of the first 1500 subjects from whom blood samples were collected, according to age and treatment groups).

End point type	Secondary
----------------	-----------

End point timeframe:

At 3 months (mths) of age (prior to dose 1); at 6 mths of age (1 mth post dose 3 or post dose 2); at 11-12 mths of age (pre-booster dose); at 14-15 mths of age (3 mths post-booster); at 18-22 mths of age (10 mths post-booster)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1803	1289	1897	
Units: Swab samples				
3 Months (N= 253, 253, 341)	57	58	76	
6 Months (N= 1803, 1289, 1897)	459	345	486	
11-12 Months (N= 1784, 1269, 1877)	671	493	733	
14-15 Months (N= 1727, 1227, 1814)	612	466	668	
18-22 Months (N= 1686, 1216, 1769)	794	566	780	

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH MORAXELLA CATARRHALIS PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH MORAXELLA CATARRHALIS PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[25]</sup>
-----------------	---

#### End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

#### End point timeframe:

At 7-11 months (mths) of age (prior to dose 1); at 9-13 mths of age (1 mth post dose 2) ; at 13-17 mths of age (pre-booster dose) ; at 16-20 mths of age ( 3 mths post-booster) ; at 23-27 mths of age (10 mths post-booster)

#### Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	200		
Units: Swab samples				
7-11 Months (N= 236, 198)	69	59		
9-13 Months (N= 230, 200)	73	61		
13-17 Months (N= 225, 197)	109	98		
16-20 Months (N= 209, 179)	91	81		
23-27 Months (N= 200, 175)	83	63		

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH MORAXELLA CATARRHALIS PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH MORAXELLA CATARRHALIS PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[26]</sup>
-----------------	--

#### End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 12-18 months (mths) of age (prior to dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	265		
Units: Swab samples				
12-18 Months (N= 358, 265)	143	72		
19-25 Months (N= 340, 255)	167	129		
21-27 Months (N= 338, 254)	143	120		

## Statistical analyses

No statistical analyses for this end point

## Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH GROUP A STREPTOCOCCUS PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH GROUP A STREPTOCOCCUS PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[27]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. The "prior to dose 1" nasopharyngeal swab samples collected from subjects within their first 7 months of age were obtained solely from the Immuno subset (The Immuno subset was constituted of the first ± 1500 subjects from whom blood samples were collected, according to age and treatment groups).

End point type	Secondary
----------------	-----------

End point timeframe:

At 3 months (mths) of age (prior to dose 1); at 6 mths of age (1 mth post dose 3 or post dose 2) ; at 11-12 mths of age (pre-booster dose) ; at 14-15 mths of age ( 3 mths post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1803	1289	1897	
Units: Swab samples				
3 Months (N= 253, 253, 341)	0	0	1	
6 Months (N= 1803, 1289, 1897)	10	5	8	

11-12 Months (N= 1784, 1269, 1877)	9	8	5	
14-15 Months (N= 1727, 1227, 1814)	4	5	10	
18-22 Months (N= 1686, 1216, 1769)	5	5	7	

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH GROUP A STREPTOCOCCUS PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH GROUP A STREPTOCOCCUS PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[28]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 7-11 months (mths) of age (prior to dose 1); at 9-13 mths of age (1 mth post dose 2) ; at 13-17 mths of age (pre-booster dose) ; at 16-20 mths of age ( 3 mths post-booster) ; at 23-27 mths of age (10 mths post-booster)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	200		
Units: Swab samples				
7-11 Months (N= 236, 198)	1	1		
9-13 Months (N= 230, 200)	0	3		
13-17 Months (N= 225, 197)	0	1		
16-20 Months (N= 209, 179)	0	2		
23-27 Months (N= 200, 175)	2	1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH GROUP A STREPTOCOCCUS PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH GROUP A STREPTOCOCCUS PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[29]</sup>
-----------------	--

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type Secondary

End point timeframe:

At 12-18 months (mths) of age (prior to dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	265		
Units: Swab samples				
12-18 Months (N= 358, 265)	3	0		
19-25 Months (N= 340, 255)	2	0		
21-27 Months (N= 338, 254)	0	2		

## Statistical analyses

No statistical analyses for this end point

## Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STAPHYLOCOCCUS AUREUS PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title NUMBER OF NASOPHARYNGEAL SWABS WITH STAPHYLOCOCCUS AUREUS PATHOGENS. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN<sup>[30]</sup>

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated. The "prior to dose 1" nasopharyngeal swab samples collected from subjects within their first 7 months of age were obtained solely from the Immuno subset (The Immuno subset was constituted of the first ± 1500 subjects from whom blood samples were collected, according to age and treatment groups).

End point type Secondary

End point timeframe:

At 3 months (mths) of age (prior to dose 1); at 6 mths of age (1 mth post dose 3 or post dose 2) ; at 11-12 mths of age (pre-booster dose) ; at 14-15 mths of age ( 3 mths post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1803	1289	1897	
Units: Swab samples				
3 Months (N= 253, 253, 341)	111	108	144	
6 Months (N= 1803, 1289, 1897)	762	515	796	
11-12 Months (N= 1784, 1269, 1877)	468	306	462	
14-15 Months (N= 1727, 1227, 1814)	387	282	373	
18-22 Months (N= 1686, 1216, 1769)	255	182	266	

## Statistical analyses

No statistical analyses for this end point

### **Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STAPHYLOCOCCUS AUREUS PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STAPHYLOCOCCUS AUREUS PATHOGENS. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[31]</sup>
-----------------	---

End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

At 7-11 months (mths) of age (prior to dose 1); at 9-13 mths of age (1 mth post dose 2) ; at 13-17 mths of age (pre-booster dose) ; at 16-20 mths of age ( 3 mths post-booster) ; at 23-27 mths of age (10 mths post-booster)

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

<b>End point values</b>	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	200		
Units: Swab samples				
7-11 Months (N= 236, 198)	60	53		
9-13 Months (N= 230, 200)	53	63		
13-17 Months (N= 225, 197)	32	26		
16-20 Months (N= 209, 179)	34	31		
23-27 Months (N= 200, 175)	30	36		

## Statistical analyses

No statistical analyses for this end point

**Secondary: NUMBER OF NASOPHARYNGEAL SWABS WITH STAPHYLOCOCCUS AUREUS PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	NUMBER OF NASOPHARYNGEAL SWABS WITH STAPHYLOCOCCUS AUREUS PATHOGENS. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[32]</sup>
-----------------	--

## End point description:

At each time point where a swab sample result was available, the number/percentage of swabs associated with the specified bacteria was tabulated.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 12-18 months (mths) of age (prior to dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

## Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	265		
Units: Swab samples				
12-18 Months (N= 358, 265)	45	38		
19-25 Months (N= 340, 255)	47	41		
21-27 Months (N= 338, 254)	39	40		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN**

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN <sup>[33]</sup>
-----------------	---

## End point description:

Antibody concentrations were measured by 22F -inhibition enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter ( $\mu\text{g}/\text{mL}$ ). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was  $\geq 0.05 \mu\text{g}/\text{mL}$ . The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 6 mths of age (1 mth post dose 3); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

## Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (3+1 schedule)

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	209	123		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-1, 6 months (N=208, 121)	1.86 (1.68 to 2.05)	0.03 (0.03 to 0.04)		
ANTI-1, 11-12 months (N= 202, 122)	0.54 (0.48 to 0.61)	0.03 (0.03 to 0.03)		
ANTI-1, 12-13 months (N= 189, 119)	2.13 (1.88 to 2.41)	0.03 (0.03 to 0.04)		
ANTI-1, 18-22 months (N= 185, 113)	0.50 (0.44 to 0.57)	0.04 (0.04 to 0.05)		
ANTI-4, 6 months (N= 208, 122)	2.47 (2.23 to 2.75)	0.03 (0.03 to 0.03)		
ANTI-4, 11-12 months (N= 203, 122)	0.97 (0.86 to 1.09)	0.03 (0.03 to 0.03)		
ANTI-4, 12-13 (N=189, 116)	3.61 (3.20 to 4.06)	0.03 (0.03 to 0.03)		
ANTI-4, 18-22 (N= 185, 113)	0.62 (0.54 to 0.71)	0.03 (0.03 to 0.03)		
ANTI-5, 6 months (N= 208, 121)	2.73 (2.47 to 3.01)	0.03 (0.03 to 0.03)		
ANTI-5, 11-12 months (N= 201, 123)	1.07 (0.95 to 1.19)	0.04 (0.04 to 0.05)		
ANTI-5, 12-13 (N= 189, 120)	3.27 (2.87 to 3.73)	0.05 (0.04 to 0.06)		
ANTI-5, 18-22 (N= 185, 113)	0.85 (0.75 to 0.97)	0.10 (0.08 to 0.13)		
ANTI-6B, 6 months (N= 208, 122)	0.51 (0.43 to 0.62)	0.03 (0.03 to 0.03)		
ANTI-6B, 11-12 months (N= 203, 123)	0.58 (0.50 to 0.67)	0.03 (0.03 to 0.03)		
ANTI-6B, 12-13 (N= 189, 120)	1.43 (1.22 to 1.68)	0.03 (0.03 to 0.03)		
ANTI-6B, 18-22 (N= 185, 113)	0.60 (0.50 to 0.72)	0.04 (0.04 to 0.05)		
ANTI-7F, 6 months (N= 209, 120)	2.90 (2.62 to 3.20)	0.03 (0.03 to 0.04)		
ANTI-7F, 11-12 months (N= 202, 122)	1.56 (1.40 to 1.74)	0.04 (0.03 to 0.04)		
ANTI-7F, 12-13 months (N= 189, 120)	4.25 (3.80 to 4.75)	0.04 (0.03 to 0.04)		
ANTI-7F, 18-22 months (N= 185, 113)	1.19 (1.07 to 1.32)	0.05 (0.04 to 0.05)		
ANTI-9V, 6 months (N= 208, 122)	2.23 (2.00 to 2.48)	0.03 (0.03 to 0.03)		
ANTI-9V, 11-12 months (N= 203, 121)	1.35 (1.20 to 1.51)	0.03 (0.03 to 0.03)		
ANTI-9V, 12-13 months (N= 188, 119)	3.98 (3.56 to 4.46)	0.03 (0.03 to 0.03)		
ANTI-9V, 18-22 months (N= 185, 113)	1.32 (1.16 to 1.50)	0.03 (0.03 to 0.04)		
ANTI-14, 6 months (N= 209, 121)	5.00 (4.46 to 5.61)	0.07 (0.06 to 0.09)		
ANTI-14, 11-12 months (N= 202, 121)	2.52 (2.19 to 2.91)	0.05 (0.04 to 0.06)		
ANTI-14, 12-13 months (N= 189, 118)	6.40 (5.62 to 7.29)	0.06 (0.05 to 0.07)		

ANTI-14, 18-22 months (N= 185, 113)	1.98 (1.70 to 2.30)	0.08 (0.06 to 0.11)		
ANTI-18C, 6 months (N= 209, 121)	6.51 (5.63 to 7.54)	0.03 (0.03 to 0.04)		
ANTI-18C, 11-12 months (N= 202, 123)	2.45 (2.10 to 2.86)	0.03 (0.03 to 0.03)		
ANTI-18C, 12-13 months (N= 189, 119)	10.43 (8.94 to 12.18)	0.03 (0.03 to 0.03)		
ANTI-18C, 18-22 months (N= 185, 113)	2.18 (1.89 to 2.53)	0.04 (0.03 to 0.04)		
ANTI-19F, 6 months (N= 209, 122)	5.91 (5.06 to 6.89)	0.06 (0.05 to 0.07)		
ANTI-19F, 11-12 months (N= 202, 122)	2.73 (2.36 to 3.16)	0.05 (0.04 to 0.06)		
ANTI-19F, 12-13 months (N= 189, 116)	8.04 (7.04 to 9.17)	0.04 (0.03 to 0.05)		
ANTI-19F, 18-22 months (N= 185, 113)	2.17 (1.84 to 2.55)	0.07 (0.05 to 0.08)		
ANTI-23F, 6 months (N= 208, 121)	0.68 (0.56 to 0.83)	0.03 (0.03 to 0.03)		
ANTI-23F, 11-12 months (N= 202, 121)	0.73 (0.62 to 0.87)	0.03 (0.03 to 0.03)		
ANTI-23F, 12-13 months (N= 189, 119)	2.30 (1.90 to 2.77)	0.03 (0.03 to 0.04)		
ANTI-23F, 18-22 months (N= 185, 113)	0.95 (0.79 to 1.13)	0.05 (0.04 to 0.06)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN <sup>[34]</sup>
-----------------	---

End point description:

Antibody concentrations were measured by 22F-inhibition enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was  $\geq 0.05$  µg/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 2); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (2+1 schedule)

<b>End point values</b>	10Pn2+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	209	142		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-1, 6 months (N= 205, 142)	1.37 (1.25 to 1.52)	0.03 (0.03 to 0.03)		
ANTI-1, 11-12 months (N= 209, 132)	0.42 (0.37 to 0.47)	0.03 (0.03 to 0.04)		
ANTI-1, 12-13 months (N= 193, 127)	1.91 (1.72 to 2.12)	0.04 (0.03 to 0.04)		
ANTI-1, 18-22 months (N= 189, 122)	0.36 (0.32 to 0.40)	0.05 (0.04 to 0.06)		
ANTI-4, 6 months (N= 204, 141)	1.87 (1.68 to 2.07)	0.03 (0.03 to 0.03)		
ANTI-4, 11-12 months (N= 209, 134)	0.72 (0.64 to 0.81)	0.03 (0.03 to 0.03)		
ANTI-4, 12-13 months (N= 193, 125)	3.16 (2.84 to 3.52)	0.03 (0.03 to 0.04)		
ANTI-4, 18-22 months (N= 189, 122)	0.59 (0.52 to 0.67)	0.03 (0.03 to 0.04)		
ANTI-5, 6 months (N= 204, 139)	1.97 (1.76 to 2.19)	0.03 (0.03 to 0.04)		
ANTI-5, 11-12 months (N= 209, 133)	0.71 (0.63 to 0.80)	0.04 (0.04 to 0.05)		
ANTI-5, 12-13 months (N= 193, 128)	2.82 (2.52 to 3.15)	0.06 (0.05 to 0.08)		
ANTI-5, 18-22 months (N= 189, 122)	0.83 (0.73 to 0.94)	0.09 (0.08 to 0.11)		
ANTI-6B, 6 months (N= 205, 142)	0.32 (0.27 to 0.37)	0.03 (0.03 to 0.03)		
ANTI-6B, 11-12 months (N= 209, 133)	0.42 (0.36 to 0.48)	0.03 (0.03 to 0.03)		
ANTI-6B, 12-13 months (N= 193, 127)	1.43 (1.25 to 1.65)	0.03 (0.03 to 0.04)		
ANTI-6B, 18-22 months (N= 189, 124)	0.58 (0.48 to 0.70)	0.06 (0.05 to 0.07)		
ANTI-7F, 6 months (N= 205, 140)	1.76 (1.57 to 1.97)	0.03 (0.03 to 0.04)		
ANTI-7F, 11-12 months (N= 209, 132)	0.96 (0.86 to 1.07)	0.03 (0.03 to 0.04)		
ANTI-7F, 12-13 months (N= 193, 129)	3.62 (3.28 to 4.01)	0.03 (0.03 to 0.04)		
ANTI-7F, 18-22 months (N= 189, 122)	1.27 (1.15 to 1.41)	0.04 (0.04 to 0.05)		
ANTI-9V, 6 months (N= 205, 140)	1.38 (1.24 to 1.54)	0.03 (0.03 to 0.03)		
ANTI-9V, 11-12 months (N= 209, 133)	0.87 (0.77 to 0.97)	0.03 (0.03 to 0.03)		
ANTI-9V, 12-13 months (N= 193, 127)	3.88 (3.47 to 4.33)	0.03 (0.03 to 0.03)		
ANTI-9V, 18-22 months (N= 189, 122)	0.92 (0.82 to 1.03)	0.04 (0.03 to 0.04)		
ANTI-14, 6 months (N= 205, 140)	3.31 (2.92 to 3.75)	0.06 (0.05 to 0.07)		
ANTI-14, 11-12 months (N= 209, 131)	1.32 (1.13 to 1.54)	0.04 (0.04 to 0.05)		
ANTI-14, 12-13 months (N= 193, 120)	4.84 (4.26 to 5.51)	0.06 (0.05 to 0.07)		

ANTI-14, 18-22 months (N= 189, 122)	1.57 (1.32 to 1.86)	0.12 (0.09 to 0.15)		
ANTI-18C, 6 months (N= 205, 141)	3.38 (2.88 to 3.95)	0.04 (0.03 to 0.04)		
ANTI-18C, 11-12 months (N= 209, 132)	1.49 (1.29 to 1.73)	0.03 (0.02 to 0.03)		
ANTI-18C, 12-13 months (N= 193, 124)	10.60 (9.48 to 11.84)	0.03 (0.03 to 0.03)		
ANTI-18C, 18-22 months (N= 189, 120)	2.16 (1.89 to 2.48)	0.04 (0.03 to 0.05)		
ANTI-19F, 6 months (N= 205, 140)	3.40 (2.92 to 3.97)	0.06 (0.05 to 0.07)		
ANTI-19F, 11-12 months (N= 209, 133)	1.51 (1.29 to 1.75)	0.03 (0.03 to 0.04)		
ANTI-19F, 12-13 months (N= 193, 124)	7.41 (6.54 to 8.40)	0.04 (0.04 to 0.05)		
ANTI-19F, 18-22 months (N= 189, 123)	2.10 (1.79 to 2.47)	0.07 (0.05 to 0.10)		
ANTI-23F, 6 months (N= 205, 142)	0.54 (0.45 to 0.65)	0.04 (0.03 to 0.04)		
ANTI-23F, 11-12 months (N= 209, 134)	0.42 (0.35 to 0.50)	0.03 (0.03 to 0.03)		
ANTI-23F, 12-13 months (N= 193,123)	2.18 (1.88 to 2.54)	0.03 (0.03 to 0.04)		
ANTI-23F, 18-22 months (N= 189, 122)	0.75 (0.63 to 0.88)	0.04 (0.04 to 0.05)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN <sup>[35]</sup>
-----------------	---

End point description:

Antibody concentrations were measured by 22F-inhibitionenzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the cross-reactive pneumococcal serotypes 6A and 19A. The cut-off of the assay was  $\geq 0.05$  µg/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 3); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (3+1 schedule)

End point values	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	208	122		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-6A, 6 months (N= 208, 120)	0.13 (0.11 to 0.15)	0.03 (0.03 to 0.04)		
ANTI-6A, 11-12 months (N= 202, 121)	0.19 (0.16 to 0.23)	0.03 (0.03 to 0.03)		
ANTI-6A, 12-13 months (N= 189, 120)	0.53 (0.43 to 0.65)	0.03 (0.03 to 0.03)		
ANTI-6A, 18-22 months (N= 185, 113)	0.30 (0.25 to 0.36)	0.04 (0.03 to 0.05)		
ANTI-19A, 6 months (N= 208, 120)	0.15 (0.12 to 0.18)	0.04 (0.04 to 0.05)		
ANTI-19A, 11-12 months (N= 202, 122)	0.23 (0.19 to 0.28)	0.03 (0.03 to 0.03)		
ANTI-19A, 12-13 months (N= 188, 117)	0.95 (0.75 to 1.19)	0.04 (0.03 to 0.05)		
ANTI-19A, 18-22 months (N= 185, 113)	0.46 (0.38 to 0.55)	0.06 (0.05 to 0.08)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN <sup>[36]</sup>
-----------------	---

#### End point description:

Antibody concentrations were measured by 22F-inhibitionenzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the cross-reactive pneumococcal serotypes 6A and 19A. The cut-off of the assay was  $\geq 0.05$  µg/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

#### End point timeframe:

At 6 mths of age (1 mth post dose 2); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age ( 1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

#### Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (2+1 schedule)

End point values	10Pn2+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	209	142		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-6A, 6 months (N= 203, 140)	0.09 (0.08 to 0.11)	0.03 (0.03 to 0.04)		
ANTI-6A, 11-12 months (N= 209, 133)	0.14 (0.12 to 0.17)	0.03 (0.03 to 0.03)		
ANTI-6A, 12-13 months (N= 193, 125)	0.50 (0.42 to 0.60)	0.03 (0.03 to 0.04)		
ANTI-6A, 18-22 months (N= 189, 124)	0.27 (0.22 to 0.33)	0.05 (0.04 to 0.06)		
ANTI-19A, 6 months (N= 204, 142)	0.13 (0.11 to 0.16)	0.04 (0.04 to 0.05)		
ANTI-19A, 11-12 months (N= 209, 132)	0.15 (0.13 to 0.19)	0.03 (0.03 to 0.03)		
ANTI-19A, 12-13 months (N= 193, 125)	0.89 (0.74 to 1.07)	0.04 (0.03 to 0.04)		
ANTI-19A, 18-22 months (N= 189, 118)	0.36 (0.30 to 0.43)	0.06 (0.05 to 0.08)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST VACCINE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN

End point title	TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST VACCINE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN <sup>[37]</sup>
-----------------	---

End point description:

Titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was  $\geq 8$ . The Immuno subset was constituted of the  $\pm$  1500 subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 3); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age ( 1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (3+1 schedule)

End point values	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	120		
Units: Titers				
geometric mean (confidence interval 95%)				

OPA-1, 6 months (N= 202, 118)	52.8 (40.7 to 68.4)	4.1 (3.9 to 4.2)		
OPA-1, 11-12 months (N= 199, 119)	13.8 (10.8 to 17.6)	4.4 (4.0 to 4.9)		
OPA-1, 12-13 months (N= 184, 120)	305.6 (238.9 to 390.8)	4.6 (4.1 to 5.1)		
OPA-1, 18-22 months (N= 184, 112)	20.9 (16.1 to 27.1)	4.1 (3.9 to 4.2)		
OPA-4, 6 months (N= 199, 112)	845.6 (746.8 to 957.4)	4.6 (3.9 to 5.5)		
OPA-4, 11-12 months (N= 190, 119)	78.7 (61.1 to 101.3)	6.0 (4.6 to 7.7)		
OPA-4, 12-13 months (N= 184, 115)	1745.7 (1476.3 to 2064.1)	5.8 (4.5 to 7.5)		
OPA-4, 18-22 months (N= 172, 109)	105.1 (75.2 to 146.8)	6.6 (4.9 to 8.8)		
OPA-5, 6 months (N= 199, 118)	65.9 (55.8 to 77.7)	4.0 (4.0 to 4.1)		
OPA-5, 11-12 months (N= 197, 119)	20.6 (16.9 to 25.0)	4.0 (4.0 to 4.0)		
OPA-5, 12-13 months (N= 185, 120)	191.6 (155.9 to 235.4)	4.1 (3.9 to 4.2)		
OPA-5, 18-22 months (N= 179, 112)	26.9 (22.1 to 32.8)	4.0 (4.0 to 4.0)		
OPA-6B, 6 months (N= 195, 111)	740.6 (558.3 to 982.4)	4.4 (3.8 to 5.0)		
OPA-6B, 11-12 months (N= 181, 116)	220.3 (161.1 to 301.1)	5.5 (4.2 to 7.2)		
OPA-6B, 12-13 months (N= 181, 117)	736.3 (576.2 to 941.0)	6.1 (4.6 to 8.2)		
OPA-6B, 18-22 months (N= 179, 106)	75.0 (51.6 to 109.0)	7.4 (5.3 to 10.4)		
OPA-7F, 6 months (N= 197, 103)	3894.8 (3320.2 to 4569.0)	87.6 (56.8 to 135.1)		
OPA-7F, 11-12 months (N= 199, 114)	1960.7 (1654.4 to 2323.7)	349.0 (252.2 to 483.0)		
OPA-7F, 12-13 months (N= 184, 117)	5219.7 (4440.2 to 6136.0)	436.7 (324.7 to 587.4)		
OPA-7F, 18-22 months (N= 183, 109)	2124.5 (1813.8 to 2488.5)	643.3 (479.5 to 863.0)		
OPA-9V, 6 months (N= 194, 112)	2798.0 (2411.9 to 3246.0)	6.5 (5.1 to 8.3)		
OPA-9V, 11-12 months (N= 198, 105)	735.3 (625.6 to 864.3)	19.4 (12.9 to 29.1)		
OPA-9V, 12-13 months (N= 183, 110)	3491.2 (3049.2 to 3997.3)	24.7 (16.0 to 38.0)		
OPA-9V, 18-22 months (N= 181, 100)	809.1 (677.0 to 966.9)	73.0 (44.9 to 118.5)		
OPA-14, 6 months (N= 198, 106)	1831.3 (1572.5 to 2132.7)	10.5 (7.5 to 14.7)		
OPA-14, 11-12 months (N= 198, 105)	529.4 (446.6 to 627.6)	18.9 (12.6 to 28.3)		
OPA-14, 12-13 months (N= 185, 109)	2657.2 (2280.6 to 3096.1)	14.1 (9.3 to 21.3)		

OPA-14, 18-22 months (N= 180, 101)	639.0 (524.6 to 778.4)	45.2 (27.4 to 74.4)		
OPA-18C, 6 months (N= 192, 116)	543.3 (444.5 to 664.2)	4.0 (4.0 to 4.0)		
OPA-18C, 11-12 months (N= 195, 118)	50.0 (38.0 to 65.7)	4.1 (3.9 to 4.3)		
OPA-18C, 12-13 months (N= 183, 118)	1066.1 (890.3 to 1276.6)	4.0 (4.0 to 4.0)		
OPA-18C, 18-22 months (N= 179, 110)	70.4 (53.7 to 92.2)	4.1 (3.9 to 4.4)		
OPA-19F, 6 months (N= 196, 118)	649.6 (522.7 to 807.4)	4.0 (4.0 to 4.0)		
OPA-19F, 11-12 months (N= 198, 117)	63.5 (49.2 to 81.9)	4.2 (3.9 to 4.6)		
OPA-19F, 12-13 months (N= 183, 119)	1026.0 (807.3 to 1303.9)	4.4 (3.9 to 4.8)		
OPA-19F, 18-22 months (N= 181, 110)	80.1 (60.2 to 106.6)	4.4 (4.0 to 4.8)		
OPA-23F, 6 months (N= 196, 111)	1900.7 (1440.0 to 2508.7)	7.0 (4.9 to 10.1)		
OPA-23F, 11-12 months (N= 191, 111)	457.1 (313.4 to 666.8)	15.9 (9.6 to 26.3)		
OPA-23F, 12-13 months (N= 184, 119)	3248.2 (2705.9 to 3899.2)	21.8 (12.9 to 37.0)		
OPA-23F, 18-22 months (N= 174, 109)	398.6 (265.6 to 598.3)	56.4 (29.9 to 106.3)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST VACCINE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN

End point title	TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST VACCINE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET, IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN <sup>[38]</sup>
-----------------	---

#### End point description:

Titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was  $\geq 8$ . The Immuno subset was constituted of the first  $\pm$  1500 subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

#### End point timeframe:

At 6 mths of age (1 mth post dose 2); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

#### Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (2+1 schedule)

<b>End point values</b>	10Pn2+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	205	139		
Units: Titers				
geometric mean (confidence interval 95%)				
OPA-1, 6 months (N= 196, 139)	38.3 (30.0 to 49.0)	4.1 (3.9 to 4.2)		
OPA-1, 11-12 months (N= 205, 132)	9.8 (8.0 to 12.0)	4.6 (4.0 to 5.3)		
OPA-1, 12-13 months (N= 185, 125)	256.9 (194.6 to 339.2)	4.2 (3.9 to 4.5)		
OPA-1, 18-22 months (N= 187, 119)	13.0 (10.2 to 16.6)	4.2 (4.0 to 4.5)		
OPA-4, 6 months (N= 192, 134)	553.0 (484.9 to 630.5)	4.8 (4.1 to 5.6)		
OPA-4, 11-12 months (N= 195, 125)	43.4 (32.9 to 57.3)	4.6 (4.0 to 5.2)		
OPA-4, 12-13 months (N= 187, 122)	1143.4 (961.9 to 1359.0)	4.7 (4.0 to 5.6)		
OPA-4, 18-22 months (N= 181, 115)	51.9 (37.5 to 72.0)	6.3 (5.0 to 7.9)		
OPA-5, 6 months (N= 195, 135)	48.5 (40.5 to 58.0)	4.0 (4.0 to 4.0)		
OPA-5, 11-12 months (N= 204, 132)	15.6 (13.1 to 18.6)	4.1 (3.9 to 4.3)		
OPA-5, 12-13 months (N= 186, 126)	145.6 (120.2 to 176.2)	4.1 (3.9 to 4.3)		
OPA-5, 18-22 months (N= 187, 119)	21.2 (17.3 to 26.1)	4.0 (4.0 to 4.0)		
OPA-6B, 6 months (N= 186, 132)	268.6 (193.3 to 373.3)	4.2 (3.8 to 4.7)		
OPA-6B, 11-12 months (N= 191, 130)	121.6 (85.9 to 172.3)	4.8 (4.0 to 5.9)		
OPA-6B, 12-13 months (N= 183, 117)	879.1 (695.4 to 1111.2)	5.3 (4.3 to 6.6)		
OPA-6B, 18-22 months (N= 173, 115)	62.0 (41.6 to 92.3)	7.9 (5.7 to 11.1)		
OPA-7F, 6 months (N= 190, 118)	2553.5 (2124.7 to 3069.0)	59.6 (38.3 to 92.6)		
OPA-7F, 11-12 months (N= 202, 124)	1454.9 (1235.2 to 1713.7)	364.8 (270.9 to 491.3)		
OPA-7F, 12-13 months (N= 185, 117)	4863.2 (4211.1 to 5616.3)	522.2 (372.4 to 732.3)		
OPA-7F, 18-22 months (N= 186, 113)	2182.7 (1910.6 to 2493.5)	856.5 (617.2 to 1188.6)		
OPA-9V, 6 months (N= 186, 130)	1687.2 (1442.7 to 1973.1)	5.3 (4.5 to 6.4)		
OPA-9V, 11-12 months (N= 198, 123)	509.4 (431.3 to 601.6)	19.3 (13.2 to 28.4)		
OPA-9V, 12-13 months (N= 179, 109)	3196.0 (2718.4 to 3757.6)	24.5 (15.9 to 37.6)		
OPA-9V, 18-22 months (N= 185, 108)	700.1 (592.5 to 827.1)	55.9 (35.4 to 88.2)		

OPA-14, 6 months (N= 191, 124)	1146.3 (944.2 to 1391.8)	7.3 (5.5 to 9.5)		
OPA-14, 11-12 months (N= 198, 123)	233.5 (185.1 to 294.7)	22.2 (14.8 to 33.1)		
OPA-14, 12-13 months (N= 187, 114)	1724.2 (1475.5 to 2014.8)	26.2 (17.3 to 39.9)		
OPA-14, 18-22 months (N= 182, 104)	463.8 (380.9 to 564.7)	99.2 (64.2 to 153.3)		
OPA-18C, 6 months (N= 184, 132)	230.6 (177.0 to 300.4)	4.0 (4.0 to 4.0)		
OPA-18C, 11-12 months (N= 197, 131)	28.9 (21.6 to 38.6)	4.1 (3.9 to 4.3)		
OPA-18C, 12-13 months (N= 183, 125)	1052.2 (881.8 to 1255.5)	4.2 (3.9 to 4.5)		
OPA-18C, 18-22 months (N= 179, 119)	84.9 (63.4 to 113.6)	6.2 (5.2 to 7.4)		
OPA-19F, 6 months (N= 187, 138)	197.6 (148.6 to 262.8)	4.1 (4.0 to 4.2)		
OPA-19F, 11-12 months (N= 204, 132)	30.1 (23.6 to 38.5)	4.2 (3.9 to 4.5)		
OPA-19F, 12-13 months (N= 186, 125)	854.6 (672.1 to 1086.6)	4.0 (4.0 to 4.0)		
OPA-19F, 18-22 months (N= 187, 116)	56.7 (42.7 to 75.3)	4.3 (4.0 to 4.7)		
OPA-23F, 6 months (N= 188, 131)	897.1 (663.5 to 1212.9)	5.6 (4.4 to 7.1)		
OPA-23F, 11-12 months (N= 202, 129)	237.2 (156.6 to 359.3)	17.3 (10.6 to 28.0)		
OPA-23F, 12-13 months (N= 184, 121)	2630.7 (2047.9 to 3379.2)	17.3 (10.6 to 28.2)		
OPA-23F, 18-22 months (N= 181, 113)	222.7 (139.3 to 356.1)	43.4 (23.8 to 79.0)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN

End point title	TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN <sup>[39]</sup>
-----------------	---

End point description:

Titers for opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A. The cut-off of the assay was  $\geq 8$ . The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 3); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (3+1 schedule)

<b>End point values</b>	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	197	119		
Units: Titers				
geometric mean (confidence interval 95%)				
OPA-6A, 6 months (N= 191, 116)	90.8 (66.4 to 124.3)	4.1 (3.9 to 4.4)		
OPA-6A, 11-12 months (N= 188, 117)	70.9 (50.7 to 99.1)	5.2 (4.2 to 6.4)		
OPA-6A, 12-13 months (N= 177, 115)	173.8 (125.7 to 240.4)	5.3 (4.3 to 6.5)		
OPA-6A, 18-22 months (N= 179, 109)	32.9 (23.2 to 46.7)	8.0 (5.9 to 11.0)		
OPA-19A, 6 months (N= 193, 118)	25.2 (18.3 to 34.8)	4.3 (3.9 to 4.8)		
OPA-19A, 11-12 months (N= 197, 118)	8.6 (7.0 to 10.7)	4.3 (3.9 to 4.8)		
OPA-19A, 12-13 months (N= 181, 119)	145.0 (104.7 to 200.9)	4.3 (4.0 to 4.8)		
OPA-19A, 18-22 months (N= 182, 111)	12.2 (9.2 to 16.1)	4.8 (4.1 to 5.7)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN

End point title	TITERS FOR OPSONOPHAGOCYtic ACTIVITY AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES 6A AND 19A, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN <sup>[40]</sup>
-----------------	---

End point description:

Titers for opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A. The cut-off of the assay was  $\geq 8$ . The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 2); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (2+1 schedule)

End point values	10Pn2+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	204	137		
Units: Titers				
geometric mean (confidence interval 95%)				
OPA-6A, 6 months (N= 183, 135)	43.1 (31.2 to 59.5)	4.4 (3.8 to 5.0)		
OPA-6A, 11-12 months (N= 195, 132)	59.0 (42.0 to 82.9)	5.1 (4.3 to 6.2)		
OPA-6A, 12-13 months (N= 168, 113)	285.9 (205.3 to 398.2)	5.3 (4.3 to 6.6)		
OPA-6A, 18-22 months (N= 167, 110)	41.8 (28.8 to 60.8)	10.5 (7.4 to 14.8)		
OPA-19A, 6 months (N= 190, 137)	11.9 (9.2 to 15.5)	4.1 (4.0 to 4.3)		
OPA-19A, 11-12 months (N= 204, 129)	5.8 (5.0 to 6.9)	4.0 (4.0 to 4.1)		
OPA-19A, 12-13 months (N= 183, 125)	78.9 (55.5 to 112.2)	4.1 (4.0 to 4.2)		
OPA-19A, 18-22 months (N= 181, 118)	8.5 (6.6 to 10.9)	5.1 (4.2 to 6.3)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: ANTIBODY CONCENTRATIONS AGAINST PROTEIN D (ANTI-PD), IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN

End point title	ANTIBODY CONCENTRATIONS AGAINST PROTEIN D (ANTI-PD), IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 3+1 INFANT SCHEDULES OF 10PN <sup>[41]</sup>
-----------------	---

End point description:

ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The cut-off of the assay was  $\geq 100$  EL.U/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 3); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (3+1 schedule)

End point values	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	209	123		
Units: EL.U/mL				
geometric mean (confidence interval 95%)				

ANTI-PD, 6 months (N= 209, 121)	1869.4 (1670.7 to 2091.7)	60.5 (54.8 to 66.7)		
ANTI-PD, 11-12 months (N= 203, 123)	955.2 (837.1 to 1089.9)	62.7 (56.4 to 69.7)		
ANTI-PD, 12-13 months (N= 188, 118)	2734.7 (2406.0 to 3108.3)	61.6 (55.0 to 69.0)		
ANTI-PD, 18-22 months (N= 185, 113 )	1030.0 (884.3 to 1199.7)	65.5 (57.4 to 74.8)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: ANTIBODY CONCENTRATIONS AGAINST PROTEIN D(ANTI-PD), IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN

End point title	ANTIBODY CONCENTRATIONS AGAINST PROTEIN D(ANTI-PD), IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 2+1 INFANT SCHEDULES OF 10PN <sup>[42]</sup>
-----------------	--

End point description:

ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The cut-off of the assay was  $\geq 100$  EL.U/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 mths of age (1 mth post dose 2); at 11-12 mths of age (pre-booster dose) ; at 12-13 mths of age (1 mth post-booster) ; at 18-22 mths of age (10 mths post-booster)

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects (2+1 schedule)

End point values	10Pn2+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	209	139		
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
ANTI-PD, 6 months (N= 203, 139)	1062.9 (936.0 to 1207.0)	66.1 (60.3 to 72.4)		
ANTI-PD, 11-12 months (N= 209, 131)	505.6 (439.2 to 582.1)	62.9 (57.0 to 69.5)		
ANTI-PD, 12-13 months (N= 193, 127)	1903.9 (1642.7 to 2206.6)	68.2 (61.1 to 76.1)		
ANTI-PD, 18-22 months (N= 188, 124)	687.7 (577.8 to 818.4)	78.6 (68.8 to 89.8)		

## Statistical analyses

**Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[43]</sup>
-----------------	---

## End point description:

Antibody concentrations were measured by 22F-inhibitionenzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was  $\geq 0.05$  µg/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 8-12 months (mths) of age (1 mth post dose 1); at 9-13 mths of age (1 mth post dose 2) ; at 13-17 mths of age (pre-booster dose) ; at 14-18 mths of age ( 1 mths post-booster) ; at 23-27 mths of age (10 mths post-booster)

## Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	101		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-1, 9-13 months (N= 151, 100)	1.96 (1.72 to 2.23)	0.03 (0.03 to 0.03)		
ANTI-1, 13-17 months (N= 144, 97)	0.66 (0.58 to 0.75)	0.04 (0.03 to 0.05)		
ANTI-1, 14-18 months (N= 137, 90)	2.62 (2.33 to 2.94)	0.04 (0.03 to 0.05)		
ANTI-1, 23-27 months (N= 124, 88)	0.59 (0.51 to 0.68)	0.05 (0.04 to 0.06)		
ANTI-4, 9-13 months (N= 150, 101)	5.85 (5.16 to 6.63)	0.03 (0.02 to 0.03)		
ANTI-4, 13-17 months (N= 144, 96)	1.55 (1.36 to 1.76)	0.03 (0.02 to 0.03)		
ANTI-4, 14-18 months (N= 135, 90)	5.45 (4.85 to 6.14)	0.03 (0.02 to 0.03)		
ANTI-4, 23-27 months (N= 124, 88)	1.21 (1.07 to 1.38)	0.03 (0.03 to 0.03)		
ANTI-5, 9-13 months (N= 151, 99)	2.40 (2.13 to 2.72)	0.04 (0.03 to 0.04)		
ANTI-5, 13-17 months (N= 144, 96)	1.19 (1.06 to 1.34)	0.06 (0.05 to 0.07)		
ANTI-5, 14-18 months (N= 137, 89)	4.11 (3.71 to 4.56)	0.07 (0.05 to 0.08)		
ANTI-5, 23-27 months (N= 123, 87)	1.30 (1.12 to 1.51)	0.13 (0.09 to 0.17)		
ANTI-6B, 9-13 months (N= 151, 100)	0.27 (0.21 to 0.33)	0.03 (0.03 to 0.03)		

ANTI-6B, 13-17 months (N= 144, 97)	0.49 (0.40 to 0.58)	0.03 (0.03 to 0.04)		
ANTI-6B, 14-18 months (N= 137, 90)	1.06 (0.85 to 1.31)	0.03 (0.03 to 0.04)		
ANTI-6B, 23-27 months (N= 124, 88)	0.52 (0.42 to 0.65)	0.06 (0.04 to 0.07)		
ANTI-7F, 9-13 months (N= 150, 100)	3.61 (3.21 to 4.06)	0.03 (0.03 to 0.03)		
ANTI-7F, 13-17 months (N= 144, 97)	2.22 (1.97 to 2.51)	0.03 (0.03 to 0.04)		
ANTI-7F, 14-18 months (N= 137, 89)	5.44 (4.80 to 6.15)	0.04 (0.03 to 0.05)		
ANTI-7F, 23-27 months (N= 123, 88)	2.08 (1.82 to 2.39)	0.05 (0.04 to 0.06)		
ANTI-9V, 9-13 months (N= 151, 100)	1.42 (1.24 to 1.64)	0.03 (0.02 to 0.03)		
ANTI-9V, 13-17 months (N= 144, 96)	0.88 (0.76 to 1.02)	0.03 (0.03 to 0.04)		
ANTI-9V, 14-18 months (N= 137, 90)	2.81 (2.44 to 3.23)	0.03 (0.03 to 0.04)		
ANTI-9V, 23-27 months (N= 123, 88)	1.16 (0.99 to 1.37)	0.03 (0.03 to 0.04)		
ANTI-14, 9-13 months (N= 150, 100)	3.81 (3.34 to 4.35)	0.05 (0.04 to 0.06)		
ANTI-14, 13-17 months (N= 144, 95)	3.06 (2.69 to 3.49)	0.08 (0.06 to 0.11)		
ANTI-14, 14-18 months (N= 137, 89)	8.38 (7.42 to 9.47)	0.10 (0.07 to 0.14)		
ANTI-14, 23-27 months (N= 123, 88)	2.91 (2.44 to 3.48)	0.13 (0.09 to 0.19)		
ANTI-18C, 9-13 months (N= 150, 101)	10.03 (8.67 to 11.61)	0.03 (0.03 to 0.03)		
ANTI-18C, 13-17 months (N= 144, 97)	4.70 (4.01 to 5.50)	0.03 (0.03 to 0.04)		
ANTI-18C, 14-18 months (N= 137, 90)	19.87 (17.08 to 23.12)	0.03 (0.03 to 0.04)		
ANTI-18C, 23-27 months (N= 123, 88)	5.46 (4.61 to 6.46)	0.04 (0.03 to 0.06)		
ANTI-19F, 9-13 months (N= 151, 100)	6.64 (5.41 to 8.15)	0.04 (0.03 to 0.05)		
ANTI-19F, 13-17 months (N= 144, 93)	3.41 (2.81 to 4.14)	0.05 (0.04 to 0.07)		
ANTI-19F, 14-18 months (N= 137, 86)	11.73 (9.73 to 14.13)	0.06 (0.04 to 0.08)		
ANTI-19F, 23-27 months (N= 124, 87)	3.69 (3.06 to 4.44)	0.09 (0.07 to 0.13)		
ANTI-23F, 9-13 months (N= 151, 100)	0.55 (0.44 to 0.70)	0.03 (0.03 to 0.03)		
ANTI-23F, 13-17 months (N= 144, 94)	0.64 (0.54 to 0.77)	0.04 (0.03 to 0.05)		
ANTI-23F, 14-18 months (N= 137, 88)	2.04 (1.71 to 2.43)	0.04 (0.03 to 0.05)		
ANTI-23F, 23-27 months (N= 123, 87)	0.80 (0.66 to 0.96)	0.06 (0.05 to 0.08)		

## Statistical analyses

**Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST PNEUMOCOCCAL VACCINE SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING RECEIVING 12-18M SCHEDULE OF 10PN <sup>[44]</sup>
-----------------	--

## End point description:

Antibody concentrations were measured by 22F-inhibitionenzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter ( $\mu\text{g/mL}$ ). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was  $\geq 0.05 \mu\text{g/mL}$ . The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

## End point timeframe:

At 13-19 months (mths) of age (1 mth post dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

## Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181	143		
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 95%)				
ANTI-1, 13-19 months (N= 181, 138)	0.73 (0.63 to 0.84)	0.04 (0.04 to 0.05)		
ANTI-1, 19-25 months (N= 167, 134)	1.87 (1.67 to 2.09)	0.04 (0.03 to 0.04)		
ANTI-1, 21-27 months (N= 162, 132)	0.95 (0.84 to 1.08)	0.04 (0.04 to 0.05)		
ANTI-4, 13-19 months (N= 181, 143)	4.64 (4.11 to 5.25)	0.03 (0.03 to 0.03)		
ANTI-4, 19-25 months (N= 167, 134)	5.28 (4.77 to 5.84)	0.03 (0.03 to 0.03)		
ANTI-4, 21-27 months (N= 162, 133)	2.57 (2.29 to 2.87)	0.03 (0.03 to 0.03)		
ANTI-5, 13-19 months (N= 181, 140)	0.77 (0.67 to 0.88)	0.07 (0.06 to 0.08)		
ANTI-5, 19-25 months (N= 167, 133)	3.45 (3.05 to 3.90)	0.07 (0.06 to 0.08)		
ANTI-5, 21-27 months (N= 162, 133)	2.14 (1.88 to 2.44)	0.08 (0.07 to 0.10)		
ANTI-6B, 13-19 months (N= 181, 136)	0.11 (0.09 to 0.13)	0.04 (0.03 to 0.04)		
ANTI-6B, 19-25 months (N= 167, 133)	0.69 (0.57 to 0.83)	0.05 (0.04 to 0.06)		
ANTI-6B, 21-27 months (N= 162, 133)	0.48 (0.40 to 0.57)	0.06 (0.05 to 0.07)		
ANTI-7F, 13-19 months (N= 181, 142)	2.53 (2.22 to 2.89)	0.03 (0.03 to 0.04)		

ANTI-7F, 19-25 months (N= 167, 134)	3.95 (3.58 to 4.35)	0.04 (0.03 to 0.05)		
ANTI-7F, 21-27 months (N= 162, 133)	2.73 (2.48 to 3.01)	0.05 (0.04 to 0.06)		
ANTI-9V, 13-19 months (N= 181, 140)	0.84 (0.73 to 0.97)	0.03 (0.03 to 0.03)		
ANTI-9V, 19-25 months (N= 167, 134)	1.60 (1.42 to 1.81)	0.03 (0.03 to 0.04)		
ANTI-9V, 21-27 months (N= 163, 129)	1.22 (1.07 to 1.39)	0.03 (0.03 to 0.04)		
ANTI-14, 13-19 months (N= 181, 143)	1.07 (0.90 to 1.28)	0.06 (0.05 to 0.08)		
ANTI-14, 19-25 months (N= 167, 132)	6.04 (5.37 to 6.79)	0.09 (0.07 to 0.12)		
ANTI-14, 21-27 months (N= 161, 133)	3.73 (3.30 to 4.21)	0.21 (0.15 to 0.29)		
ANTI-18C, 13-19 months (N= 181,142)	3.76 (3.35 to 4.22)	0.04 (0.03 to 0.04)		
ANTI-18C, 19-25 months (N= 166, 134)	21.27 (18.70 to 24.19)	0.04 (0.03 to 0.04)		
ANTI-18C, 21-27 months (N= 162, 133)	12.44 (10.88 to 14.22)	0.04 (0.03 to 0.05)		
ANTI-19F, 13-19 months (N= 181, 143)	2.63 (2.24 to 3.10)	0.06 (0.05 to 0.08)		
ANTI-19F, 19-25 months (N= 166, 134)	12.10 (10.38 to 14.11)	0.09 (0.07 to 0.12)		
ANTI-19F, 21-27 months (N= 162, 132)	8.49 (7.39 to 9.74)	0.11 (0.08 to 0.15)		
ANTI-23F, 13-19 months (N= 181, 138)	0.16 (0.13 to 0.19)	0.03 (0.03 to 0.04)		
ANTI-23F, 19-25 months (N= 167, 134)	1.27 (1.07 to 1.50)	0.05 (0.04 to 0.06)		
ANTI-23F, 21-27 months (N= 162, 132)	0.83 (0.70 to 0.99)	0.05 (0.04 to 0.06)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[45]</sup>
-----------------	--

#### End point description:

Antibody concentrations were measured by 22F-inhibitionenzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter ( $\mu\text{g}/\text{mL}$ ). Serotypes assessed were the cross-reactive pneumococcal serotypes 6A and 19A. The cut-off of the assay was  $\geq 0.05 \mu\text{g}/\text{mL}$ . The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

#### End point timeframe:

At 8-12 months (mths) of age (1 mth post dose 1); at 9-13 mths of age (1 mth post dose 2) ; at 13-17 mths of age (pre-booster dose) ; at 14-18 mths of age ( 1 mths post-booster) ; at 23-27 mths of age (10 mths post-booster)

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

<b>End point values</b>	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	100		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-6A, 9-13 months (N= 150, 99)	0.11 (0.09 to 0.14)	0.03 (0.03 to 0.03)		
ANTI-6A, 13-17 months (N= 144, 96)	0.23 (0.18 to 0.29)	0.03 (0.03 to 0.04)		
ANTI-6A, 14-18 months (N= 137, 89)	0.70 (0.55 to 0.90)	0.03 (0.03 to 0.04)		
ANTI-6A, 23-27 months (N= 123, 88)	0.33 (0.26 to 0.41)	0.06 (0.04 to 0.07)		
ANTI-19A, 9-13 months (N= 151, 100)	0.33 (0.26 to 0.42)	0.04 (0.03 to 0.04)		
ANTI-19A, 13-17 months (N= 144, 97)	0.49 (0.39 to 0.62)	0.05 (0.04 to 0.06)		
ANTI-19A, 14-18 months (N= 137, 90)	1.98 (1.53 to 2.56)	0.04 (0.04 to 0.06)		
ANTI-19A, 23-27 months (N= 123, 88)	0.93 (0.70 to 1.23)	0.08 (0.06 to 0.11)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING RECEIVING 12-18M SCHEDULE OF 10PN

End point title	PNEUMOCOCCAL ANTIBODY CONCENTRATIONS AGAINST CROSS-REACTIVE PNEUMOCOCCAL SEROTYPES, IN THE IMMUNO SUBSET. IN SUBJECTS RECEIVING RECEIVING 12-18M SCHEDULE OF 10PN <sup>[46]</sup>
-----------------	---

End point description:

Antibody concentrations were measured by 22F-inhibitionenzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the cross-reactive pneumococcal serotypes 6A and 19A. The cut-off of the assay was  $\geq 0.05$  µg/mL. The Immuno subset was constituted of the first  $\pm 1500$  subjects from whom blood samples were collected, according to age and treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

At 13-19 months (mths) of age (1 mth post dose 1); at 19-25 mths of age (1 mth post dose 2); at 21-27 mths of age (3 months post dose 2)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181	143		
Units: µg/mL				
geometric mean (confidence interval 95%)				
ANTI-6A, 13-19 months (N= 181, 143)	0.06 (0.05 to 0.08)	0.04 (0.03 to 0.04)		
ANTI-6A, 19-25 months (N= 167, 134)	0.32 (0.26 to 0.41)	0.05 (0.04 to 0.06)		
ANTI-6A, 21-27 months (N= 162, 132)	0.29 (0.23 to 0.36)	0.06 (0.05 to 0.08)		
ANTI-19A, 13-19 months (N= 181, 136)	0.20 (0.16 to 0.25)	0.05 (0.04 to 0.06)		
ANTI-19A, 19-25 months (N= 167, 134)	2.61 (2.12 to 3.22)	0.06 (0.05 to 0.07)		
ANTI-19A, 21-27 months (N= 162, 132)	1.72 (1.41 to 2.10)	0.07 (0.05 to 0.09)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[47]</sup>
-----------------	---

#### End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

#### End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) follow-up period (31 January 2012).

#### Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1846	942	1329	
Units: Participants per 1000 person-years				
number (confidence interval 95%)	420.645 (396.814 to 445.534)	415.560 (382.673 to 450.518)	443.411 (414.786 to 473.491)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[48]</sup>
-----------------	---

End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	191	96		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	510.388 (422.105 to 611.686)	590.118 (460.887 to 744.354)		

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

---

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[49]</sup>
-----------------	--

End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

End point values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	106		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	598.065 (502.777 to 706.159)	567.194 (419.613 to 749.861)		

---

**Statistical analyses**

No statistical analyses for this end point

---

**Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH RECURRENT ACUTE OTITIS MEDIA (AOM) EPISODES ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN**

---

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH RECURRENT ACUTE OTITIS MEDIA (AOM) EPISODES ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[50]</sup>
-----------------	--

End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management

guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1846	942	1329	
Units: Participants per 1000 person-years				
number (confidence interval 95%)	100.550 (89.076 to 113.091)	103.008 (86.977 to 121.137)	94.946 (81.957 to 109.407)	

## Statistical analyses

No statistical analyses for this end point

### **Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH RECURRENT ACUTE OTITIS MEDIA (AOM) EPISODES ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH RECURRENT ACUTE OTITIS MEDIA (AOM) EPISODES ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[51]</sup>
-----------------	--

End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

<b>End point values</b>	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	191	96		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	78.521 (46.537 to 124.097)	132.984 (76.012 to 215.958)		

## Statistical analyses

No statistical analyses for this end point

### **Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH RECURRENT ACUTE OTITIS MEDIA (AOM) EPISODES ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH RECURRENT ACUTE OTITIS MEDIA (AOM) EPISODES ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[52]</sup>
-----------------	---

End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	106		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	90.355 (55.931 to 138.117)	46.302 (12.616 to 118.550)		

## Statistical analyses

**Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY AND ACCOMPANIED WITH DOCUMENTED ANTIMICROBIAL PRESCRIPTION. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN**

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY AND ACCOMPANIED WITH DOCUMENTED ANTIMICROBIAL PRESCRIPTION. IN SUBJECTS RECEIVING 3+1 AND 2+1 INFANT SCHEDULES OF 10PN <sup>[53]</sup>
-----------------	--

## End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

## End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

## Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 6W-6M subjects

End point values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl-6W-6M/053 Group	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	1846	942	1329	
Units: Participants per 1000 person-years				
number (confidence interval 95%)	409.795 (386.277 to 434.369)	408.505 (375.904 to 443.176)	430.984 (402.769 to 460.653)	

### Statistical analyses

No statistical analyses for this end point

**Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY AND ACCOMPANIED WITH DOCUMENTED ANTIMICROBIAL PRESCRIPTION. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN**

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY AND ACCOMPANIED WITH DOCUMENTED ANTIMICROBIAL PRESCRIPTION. IN SUBJECTS RECEIVING 7-11M SCHEDULE OF 10PN <sup>[54]</sup>
-----------------	--

## End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period

expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 7-11M subjects

End point values	10Pn7-11M/053 Group	Ctrl7-11M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	191	96		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	497.301 (410.212 to 597.410)	581.807 (453.547 to 735.078)		

## Statistical analyses

No statistical analyses for this end point

### **Secondary: PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY AND ACCOMPANIED WITH DOCUMENTED ANTIMICROBIAL PRESCRIPTION. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN**

End point title	PERSON YEAR RATE AS REGARDS SUBJECTS WITH ACUTE OTITIS MEDIA (AOM) EPISODE ASSESSED AS WITH LEVEL 1 OF DIAGNOSTIC CERTAINTY AND ACCOMPANIED WITH DOCUMENTED ANTIMICROBIAL PRESCRIPTION. IN SUBJECTS RECEIVING 12-18M SCHEDULE OF 10PN <sup>[55]</sup>
-----------------	---

End point description:

The PYAR (Person-Year Rate) as regards subjects with AOM episode was tabulated. PYAR was calculated as follows  $n$  (= number of subjects reported with event) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000). An AOM episode assessed as with level 1 of diagnostic certainty was defined as an AOM event diagnosed by a physician according to the Finnish AOM management guidelines (confirmed cases) and reported by subjects' parent(s)/guardian(s) regardless the documentation in medical records or other source document. Note that a post-hoc re-analysis of AOM endpoints with a corrected definition of follow-up taking into account individual end of follow-up time was performed; the results of re-analysis as the most prominent for AOM outcome are presented in this summary.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was anytime after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (31 January 2012).

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point analysis has been performed on 12-18M subjects

<b>End point values</b>	10Pn12-18M/053 Group	Ctrl12-18M/053 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	106		
Units: Participants per 1000 person-years				
number (confidence interval 95%)	593.763 (498.833 to 701.499)	555.619 (409.670 to 736.670)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Culture-confirmed Invasive Disease (ID) Person Year Rate - In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course till end of LT FU period.

End point title	Culture-confirmed Invasive Disease (ID) Person Year Rate - In children starting vaccination within 7 months of life and assigned to a 3-dose primary vaccination course till end of LT FU period.
-----------------	---

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the long-term Follow-up period (The Follow-up period lasted at least 77 months).

<b>End point values</b>	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10272	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Culture confirmed ID	0.046 (0.013 to 0.118)	0.268 (0.170 to 0.402)		
Pneumococcal invasive disease (IPD)	0.023 (0.003 to 0.084)	0.210 (0.124 to 0.331)		
Vaccine serotypes (vaccine type-IPD)	0.0 (0.0 to 0.043)	0.140 (0.072 to 0.244)		

Serotype 4	0.0 (0.0 to 0.043)	0.0 (0.0 to 0.043)		
Serotype 6B	0.0 (0.0 to 0.043)	0.058 (0.019 to 0.136)		
Serotype 7F	0.0 (0.0 to 0.043)	0.0 (0.0 to 0.043)		
Serotype 14	0.0 (0.0 to 0.043)	0.047 (0.013 to 0.119)		
Serotype 18C	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Serotype 19F	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Serotype 23F	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Cross-reactive serotypes	0.012 (0.0 to 0.064)	0.047 (0.013 to 0.119)		
Serotype 6A	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Serotype 19A	0.012 (0.0 to 0.064)	0.035 (0.007 to 0.102)		
Other pneumococcal serotypes	0.012 (0.0 to 0.064)	0.023 (0.003 to 0.084)		
Serotype 3	0.012 (0.0 to 0.064)	0.012 (0.0 to 0.065)		
Serotype 12F	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Serotype 15C	0.0 (0.0 to 0.043)	0.0 (0.0 to 0.043)		
H. influenzae ID	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Non-typeable (NTHI)	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		
Other bacteria	0.023 (0.003 to 0.084)	0.058 (0.019 to 0.136)		
Neisseria meningitidis	0.023 (0.003 to 0.084)	0.023 (0.003 to 0.084)		
Streptococcus pyogenes	0.0 (0.0 to 0.043)	0.023 (0.003 to 0.084)		
Moraxella catarrhalis	0.0 (0.0 to 0.043)	0.012 (0.0 to 0.065)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Culture-confirmed Invasive Disease (ID) Person Year Rate - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course till end of LT FU period.

End point title	Culture-confirmed Invasive Disease (ID) Person Year Rate - In children starting vaccination within 7 months of life and assigned to a 2-dose primary vaccination course till end of LT FU period.
-----------------	---

End point description:

The PYAR (Person-Year Rate) was calculated as follows  $n$  (= number of subjects reported with a culture confirmed IPD) divided by  $T$  (= sum of follow-up period expressed in years) (per 1000) as well as the corresponding 95% confidence interval (CI), calculated as a 2-sided profile log-likelihood ratio 95% CI using a classical log linear Poisson regression with strata.

End point type	Secondary
----------------	-----------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the long-term Follow-up period (The Follow-up period lasted at least 77 months).

<b>End point values</b>	10Pn2+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10053	10201		
Units: Participants per 1000 person-years				
number (confidence interval 95%)				
Culture confirmed ID	0.047 (0.013 to 0.122)	0.268 (0.170 to 0.402)		
Pneumococcal invasive disease (IPD)	0.024 (0.003 to 0.086)	0.210 (0.124 to 0.331)		
Vaccine serotypes (vaccine type-IPD)	0.012 (0.0 to 0.066)	0.140 (0.072 to 0.244)		
Serotype 4	0.0 (0.0 to 0.044)	0.0 (0.0 to 0.043)		
Serotype 6B	0.0 (0.0 to 0.044)	0.058 (0.019 to 0.136)		
Serotype 7F	0.012 (0.0 to 0.066)	0.0 (0.0 to 0.043)		
Serotype 14	0.0 (0.0 to 0.044)	0.047 (0.013 to 0.119)		
Serotype 18C	0.0 (0.0 to 0.044)	0.012 (0.0 to 0.065)		
Serotype 19F	0.0 (0.0 to 0.044)	0.012 (0.0 to 0.065)		
Serotype 23F	0.0 (0.0 to 0.044)	0.012 (0.0 to 0.065)		
Cross-reactive serotypes	0.0 (0.0 to 0.044)	0.047 (0.013 to 0.119)		
Serotype 6A	0.0 (0.0 to 0.044)	0.012 (0.0 to 0.065)		
Serotype 19A	0.0 (0.0 to 0.044)	0.035 (0.007 to 0.102)		
Other pneumococcal serotypes	0.012 (0.0 to 0.065)	0.023 (0.003 to 0.084)		
Serotype 3	0.012 (0.0 to 0.066)	0.012 (0.0 to 0.065)		
Serotype 12F	0.0 (0.0 to 0.044)	0.012 (0.0 to 0.065)		
Serotype 15C	0.0 (0.0 to 0.044)	0.0 (0.0 to 0.043)		
H. influenzae ID	0.012 (0.0 to 0.066)	0.012 (0.0 to 0.065)		
Non-typeable (NTHI)	0.012 (0.0 to 0.066)	0.012 (0.0 to 0.065)		
Other bacteria	0.012 (0.0 to 0.066)	0.058 (0.019 to 0.136)		
Neisseria meningitidis	0.012 (0.0 to 0.066)	0.023 (0.003 to 0.084)		
Streptococcus pyogenes	0.0 (0.0 to 0.044)	0.023 (0.003 to 0.084)		
Moraxella catarrhalis	0.0 (0.0 to 0.044)	0.012 (0.0 to 0.065)		

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

---

### Adverse events information

---

Timeframe for reporting adverse events:

Solicited & unsolicited AEs: 4-day & 31-day post primary/booster vaccination. SAEs from Day 0 to study end: Month (M)18 for 6W-6M groups, M16 for 7-11M groups and M9 for M12-18 groups. Non-serious AE Threshold=4.98% but corrected to 5% (system constraint)

---

Adverse event reporting additional description:

To avoid inconsistency between the AE reporting and the acute otitis media (AOM) questionnaire filled in by subjects' parent(s)/LAR(s), otitis was not reported as an AE if already reported via the AOM questionnaire. Number of occurrences were not available at the time of the analysis, then put equal to number of subjects affected.

---

Assessment type	Systematic
-----------------	------------

---

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

---

Dictionary version	15.0
--------------------	------

---

### Reporting groups

Reporting group title	Ctrl3+1-6W-6M/053 Group
-----------------------	-------------------------

---

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

---

Reporting group title	Ctrl2+1-6W-6M/053 Group
-----------------------	-------------------------

---

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

---

Reporting group title	10Pn3+1-6W-6M/053 Group
-----------------------	-------------------------

---

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

---

Reporting group title	Ctrl12-18M/053 Group
-----------------------	----------------------

---

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

---

Reporting group title	10Pn7-11M/053 Group
-----------------------	---------------------

---

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

---

Reporting group title	Ctrl7-11M/053 Group
-----------------------	---------------------

---

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	10Pn2+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

<b>Serious adverse events</b>	Ctrl3+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group	10Pn3+1-6W-6M/053 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	77 / 1069 (7.20%)	74 / 859 (8.61%)	163 / 1849 (8.82%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	4 / 1069 (0.37%)	2 / 859 (0.23%)	4 / 1849 (0.22%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Crying			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Developmental delay			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Milk allergy			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic reaction			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	4 / 1069 (0.37%)	3 / 859 (0.35%)	4 / 1849 (0.22%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cough			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Cardiac murmur			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	2 / 1069 (0.19%)	1 / 859 (0.12%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	1 / 1069 (0.09%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			

subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Contusion</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Electric shock</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Joint dislocation</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Poisoning</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Concussion</b>			
subjects affected / exposed	0 / 1069 (0.00%)	2 / 859 (0.23%)	3 / 1849 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Burns second degree</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Chemical poisoning</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skull fracture</b>			

subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental drug intake by child			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental poisoning			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Amaurotic familial idiocy			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patent ductus arteriosus			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular septal defect			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Combined immunodeficiency			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniosynostosis			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyloric stenosis			

subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Coarctation of the aorta</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Krabbe's disease</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Mitochondrial encephalomyopathy</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
<b>Cyanosis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pericardial effusion</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>Febrile convulsion</b>			
subjects affected / exposed	1 / 1069 (0.09%)	2 / 859 (0.23%)	5 / 1849 (0.27%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Convulsion</b>			
subjects affected / exposed	2 / 1069 (0.19%)	1 / 859 (0.12%)	5 / 1849 (0.27%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Epilepsy</b>			

subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperreflexia</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Loss of consciousness</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorder</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Petit mal epilepsy</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Altered state of consciousness</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Balance disorder</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cerebral infarction</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cognitive disorder</b>			

subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Aplasia pure red cell			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			

subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroesophageal reflux disease</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Inguinal hernia</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Inguinal hernia strangulated</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vomiting</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Melaena</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Urticaria</b>			
subjects affected / exposed	1 / 1069 (0.09%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Erythema</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Subcutaneous abscess</b>			

subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eczema nummular</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Juvenile arthritis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neck pain</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	19 / 1069 (1.78%)	20 / 859 (2.33%)	33 / 1849 (1.78%)
occurrences causally related to treatment / all	0 / 19	0 / 20	0 / 33
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Otitis media</b>			
subjects affected / exposed	9 / 1069 (0.84%)	13 / 859 (1.51%)	22 / 1849 (1.19%)
occurrences causally related to treatment / all	0 / 9	0 / 13	0 / 22
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchiolitis</b>			
subjects affected / exposed	5 / 1069 (0.47%)	9 / 859 (1.05%)	9 / 1849 (0.49%)
occurrences causally related to treatment / all	0 / 5	0 / 9	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis</b>			
subjects affected / exposed	5 / 1069 (0.47%)	4 / 859 (0.47%)	15 / 1849 (0.81%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Laryngitis			
subjects affected / exposed	4 / 1069 (0.37%)	7 / 859 (0.81%)	12 / 1849 (0.65%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	4 / 1069 (0.37%)	4 / 859 (0.47%)	11 / 1849 (0.59%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	3 / 1069 (0.28%)	5 / 859 (0.58%)	10 / 1849 (0.54%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	2 / 1069 (0.19%)	2 / 859 (0.23%)	10 / 1849 (0.54%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	3 / 1069 (0.28%)	3 / 859 (0.35%)	5 / 1849 (0.27%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	1 / 1069 (0.09%)	3 / 859 (0.35%)	5 / 1849 (0.27%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 1069 (0.19%)	2 / 859 (0.23%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 1069 (0.00%)	2 / 859 (0.23%)	4 / 1849 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	1 / 1069 (0.09%)	1 / 859 (0.12%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia respiratory syncytial viral</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tonsillitis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Adenovirus infection</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bacterial infection</b>			
subjects affected / exposed	2 / 1069 (0.19%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumococcal sepsis</b>			
subjects affected / exposed	2 / 1069 (0.19%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Anal abscess</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Enterovirus infection</b>			

subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>H1N1 influenza</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	2 / 1849 (0.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Influenza</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory syncytial virus bronchitis</b>			
subjects affected / exposed	2 / 1069 (0.19%)	4 / 859 (0.47%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Abscess neck</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bacterial sepsis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Croup infectious</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ear infection</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Groin abscess</b>			

subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis viral			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngomalacia			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningococcal sepsis			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal bacteraemia			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			

subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia bacterial</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory tract infection viral</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Staphylococcal sepsis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Streptococcal infection</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tracheitis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Viral infection</b>			
subjects affected / exposed	4 / 1069 (0.37%)	1 / 859 (0.12%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis acute</b>			
subjects affected / exposed	1 / 1069 (0.09%)	3 / 859 (0.35%)	4 / 1849 (0.22%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Streptococcal sepsis</b>			

subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema infected			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exanthema subitum			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impetigo			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			

subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Mastoiditis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Osteomyelitis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Parainfluenzae virus infection</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Septic arthritis streptococcal</b>			
subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Diarrhoea infectious</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Escherichia sepsis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Otitis media fungal</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia viral</b>			

subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory tract infection</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Roseola</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Rotavirus infection</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis viral</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cellulitis</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cellulitis orbital</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Viral upper respiratory tract infection</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Type 1 diabetes mellitus			

subjects affected / exposed	0 / 1069 (0.00%)	1 / 859 (0.12%)	1 / 1849 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Weight gain poor</b>			
subjects affected / exposed	1 / 1069 (0.09%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dehydration</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypoglycaemia</b>			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Ctrl12-18M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	14 / 271 (5.17%)	24 / 241 (9.96%)	18 / 204 (8.82%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Haemangioma</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
<b>Hypertension</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			
<b>Pyrexia</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Crying</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Developmental delay</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sudden death</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Immune system disorders</b>			
<b>Milk allergy</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Anaphylactic reaction</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>Asthma</b>			
subjects affected / exposed	2 / 271 (0.74%)	4 / 241 (1.66%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dyspnoea</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Apnoea			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Cardiac murmur			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			

subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tibia fracture</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Contusion</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Electric shock</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Joint dislocation</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Poisoning</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Concussion</b>			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Burns second degree</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Chemical poisoning</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skull fracture</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Accidental drug intake by child</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Accidental poisoning</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Congenital, familial and genetic disorders</b>			
<b>Amaurotic familial idiocy</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Patent ductus arteriosus</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ventricular septal defect</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Combined immunodeficiency</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Craniosynostosis</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyloric stenosis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Coarctation of the aorta</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Krabbe's disease</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Mitochondrial encephalomyopathy</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
<b>Cyanosis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pericardial effusion</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>Febrile convulsion</b>			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Convulsion</b>			

subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperreflexia			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Altered state of consciousness			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Balance disorder			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cognitive disorder</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dysarthria</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Aplasia pure red cell</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lymphadenitis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Diarrhoea</b>			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Enteritis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Intussusception</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis adenovirus</b>			

subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis rotavirus</b>			
subjects affected / exposed	1 / 271 (0.37%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrooesophageal reflux disease</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Inguinal hernia</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Inguinal hernia strangulated</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vomiting</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Melaena</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Urticaria</b>			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Erythema</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Subcutaneous abscess</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eczema nummular</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Juvenile arthritis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neck pain</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	2 / 271 (0.74%)	9 / 241 (3.73%)	5 / 204 (2.45%)
occurrences causally related to treatment / all	0 / 2	0 / 9	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Otitis media</b>			
subjects affected / exposed	2 / 271 (0.74%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchiolitis</b>			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	2 / 204 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastroenteritis			
subjects affected / exposed	1 / 271 (0.37%)	3 / 241 (1.24%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 271 (0.37%)	1 / 241 (0.41%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	0 / 271 (0.00%)	2 / 241 (0.83%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal sepsis			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 influenza			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess neck			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup infectious			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear infection			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Groin abscess</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Herpes zoster</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Laryngitis viral</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Laryngomalacia</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lymph gland infection</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Meningococcal sepsis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pharyngitis</b>			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumococcal bacteraemia</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumococcal infection</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia bacterial</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory tract infection viral</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Staphylococcal sepsis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Streptococcal infection</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tracheitis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Viral infection</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis acute</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	2 / 204 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Streptococcal sepsis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Varicella</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cystitis</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eczema infected</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Exanthema subitum</b>			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis norovirus</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hand-foot-and-mouth disease</b>			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Impetigo</b>			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic arthritis streptococcal			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media fungal			

subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Roseola			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			
subjects affected / exposed	0 / 271 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis orbital			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Type 1 diabetes mellitus			
subjects affected / exposed	1 / 271 (0.37%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight gain poor			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 271 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	10Pn2+1-6W-6M/053 Group	10Pn12-18M/053 Group	
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	96 / 1316 (7.29%)	23 / 368 (6.25%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	0	0	
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
Haemangioma			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vascular disorders</b>			
Hypertension			

subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General disorders and administration site conditions</b>			
Pyrexia			
subjects affected / exposed	4 / 1316 (0.30%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crying			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Developmental delay			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Immune system disorders</b>			
Milk allergy			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
Asthma			

subjects affected / exposed	2 / 1316 (0.15%)	4 / 368 (1.09%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dyspnoea</b>			
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Apnoea</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cough</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Psychiatric disorders</b>			
<b>Breath holding</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Confusional state</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
<b>Cardiac murmur</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
<b>Femur fracture</b>			
subjects affected / exposed	1 / 1316 (0.08%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Foreign body			
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electric shock			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			

subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemical poisoning			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental drug intake by child			
subjects affected / exposed	0 / 1316 (0.00%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental poisoning			
subjects affected / exposed	0 / 1316 (0.00%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Amaurotic familial idiocy			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patent ductus arteriosus			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular septal defect			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Combined immunodeficiency			

subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Craniosynostosis</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pyloric stenosis</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Coarctation of the aorta</b>			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Krabbe's disease</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Mitochondrial encephalomyopathy</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>Cyanosis</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pericardial effusion</b>			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			

Febrile convulsion			
subjects affected / exposed	6 / 1316 (0.46%)	2 / 368 (0.54%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Convulsion			
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperreflexia			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			

subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebral infarction</b>			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cognitive disorder</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dysarthria</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Aplasia pure red cell</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lymphadenitis</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Diarrhoea</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Enteritis</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Intussusception</b>			

subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastroenteritis adenovirus</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastroenteritis rotavirus</b>			
subjects affected / exposed	0 / 1316 (0.00%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrooesophageal reflux disease</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Inguinal hernia</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Inguinal hernia strangulated</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vomiting</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Melaena</b>			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
Urticaria			

subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema nummular			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Juvenile arthritis			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	13 / 1316 (0.99%)	5 / 368 (1.36%)	
occurrences causally related to treatment / all	0 / 13	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	7 / 1316 (0.53%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bronchiolitis			
subjects affected / exposed	8 / 1316 (0.61%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 8	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	7 / 1316 (0.53%)	2 / 368 (0.54%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	6 / 1316 (0.46%)	2 / 368 (0.54%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	7 / 1316 (0.53%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	5 / 1316 (0.38%)	2 / 368 (0.54%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	7 / 1316 (0.53%)	2 / 368 (0.54%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	3 / 1316 (0.23%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media acute			
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			

subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Respiratory syncytial virus infection</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Urinary tract infection</b>		
subjects affected / exposed	2 / 1316 (0.15%)	1 / 368 (0.27%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Infection</b>		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Pneumonia respiratory syncytial viral</b>		
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Tonsillitis</b>		
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Adenovirus infection</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Bacterial infection</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Pneumococcal sepsis</b>		

subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Anal abscess</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Enterovirus infection</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>H1N1 influenza</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Influenza</b>		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Respiratory syncytial virus bronchitis</b>		
subjects affected / exposed	7 / 1316 (0.53%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Abscess neck</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Bacterial sepsis</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Croup infectious</b>		

subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis viral			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngomalacia			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymph gland infection			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningococcal sepsis			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			

subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Pneumococcal bacteraemia</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Pneumococcal infection</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Pneumonia bacterial</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Respiratory tract infection viral</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Staphylococcal sepsis</b>		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Streptococcal infection</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Tracheitis</b>		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Viral infection</b>		

subjects affected / exposed	3 / 1316 (0.23%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pyelonephritis acute		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Streptococcal sepsis		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Varicella		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cystitis		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Eczema infected		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Exanthema subitum		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis norovirus		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hand-foot-and-mouth disease		

subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Impetigo		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Lobar pneumonia		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Mastoiditis		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Osteomyelitis		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Parainfluenzae virus infection		
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Septic arthritis streptococcal		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Diarrhoea infectious		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Escherichia sepsis		

subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Otitis media fungal		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia viral		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Roseola		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Rotavirus infection		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis viral		
subjects affected / exposed	0 / 1316 (0.00%)	2 / 368 (0.54%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Cellulitis		
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cellulitis orbital		

subjects affected / exposed	0 / 1316 (0.00%)	1 / 368 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight gain poor			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	2 / 1316 (0.15%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	1 / 1316 (0.08%)	0 / 368 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Ctrl3+1-6W-6M/053 Group	Ctrl2+1-6W-6M/053 Group	10Pn3+1-6W-6M/053 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1038 / 1069 (97.10%)	805 / 859 (93.71%)	1840 / 1849 (99.51%)
Nervous system disorders			
Somnolence			
subjects affected / exposed	723 / 1069 (67.63%)	539 / 859 (62.75%)	1493 / 1849 (80.75%)
occurrences (all)	1394	887	3305

General disorders and administration site conditions			
Injection site induration			
subjects affected / exposed	71 / 1069 (6.64%)	29 / 859 (3.38%)	419 / 1849 (22.66%)
occurrences (all)	89	34	720
Pain			
subjects affected / exposed	396 / 1069 (37.04%)	275 / 859 (32.01%)	1399 / 1849 (75.66%)
occurrences (all)	614	374	2898
Pyrexia			
subjects affected / exposed	377 / 1069 (35.27%)	261 / 859 (30.38%)	1030 / 1849 (55.71%)
occurrences (all)	483	334	1621
Swelling			
subjects affected / exposed	382 / 1069 (35.73%)	205 / 859 (23.86%)	1257 / 1849 (67.98%)
occurrences (all)	575	262	2716
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	75 / 1069 (7.02%)	52 / 859 (6.05%)	140 / 1849 (7.57%)
occurrences (all)	84	58	160
Teething			
subjects affected / exposed	61 / 1069 (5.71%)	34 / 859 (3.96%)	66 / 1849 (3.57%)
occurrences (all)	70	39	83
Vomiting			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	584 / 1069 (54.63%)	397 / 859 (46.22%)	1522 / 1849 (82.31%)
occurrences (all)	1188	665	3821
Psychiatric disorders			
Irritability			
subjects affected / exposed	914 / 1069 (85.50%)	688 / 859 (80.09%)	1761 / 1849 (95.24%)
occurrences (all)	2134	1304	4864

Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	64 / 1069 (5.99%)	64 / 859 (7.45%)	107 / 1849 (5.79%)
occurrences (all)	87	74	127
Otitis media			
subjects affected / exposed	57 / 1069 (5.33%)	24 / 859 (2.79%)	69 / 1849 (3.73%)
occurrences (all)	65	24	80
Rhinitis			
subjects affected / exposed	105 / 1069 (9.82%)	72 / 859 (8.38%)	147 / 1849 (7.95%)
occurrences (all)	123	83	178
Upper respiratory tract infection			
subjects affected / exposed	131 / 1069 (12.25%)	45 / 859 (5.24%)	233 / 1849 (12.60%)
occurrences (all)	161	53	291
Gastroenteritis			
subjects affected / exposed	0 / 1069 (0.00%)	0 / 859 (0.00%)	0 / 1849 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	527 / 1069 (49.30%)	356 / 859 (41.44%)	1103 / 1849 (59.65%)
occurrences (all)	828	483	1832

<b>Non-serious adverse events</b>	Ctrl12-18M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	254 / 271 (93.73%)	232 / 241 (96.27%)	193 / 204 (94.61%)
Nervous system disorders			
Somnolence			
subjects affected / exposed	118 / 271 (43.54%)	165 / 241 (68.46%)	101 / 204 (49.51%)
occurrences (all)	145	286	161
General disorders and administration site conditions			
Injection site induration			
subjects affected / exposed	2 / 271 (0.74%)	30 / 241 (12.45%)	5 / 204 (2.45%)
occurrences (all)	2	47	6
Pain			
subjects affected / exposed	116 / 271 (42.80%)	176 / 241 (73.03%)	76 / 204 (37.25%)
occurrences (all)	143	351	111
Pyrexia			

subjects affected / exposed occurrences (all)	62 / 271 (22.88%) 70	115 / 241 (47.72%) 154	68 / 204 (33.33%) 77
Swelling subjects affected / exposed occurrences (all)	42 / 271 (15.50%) 51	154 / 241 (63.90%) 290	50 / 204 (24.51%) 68
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	25 / 271 (9.23%) 28	22 / 241 (9.13%) 27	17 / 204 (8.33%) 19
Teething subjects affected / exposed occurrences (all)	0 / 271 (0.00%) 0	11 / 241 (4.56%) 15	21 / 204 (10.29%) 21
Vomiting subjects affected / exposed occurrences (all)	0 / 271 (0.00%) 0	12 / 241 (4.98%) 13	7 / 204 (3.43%) 7
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	15 / 271 (5.54%) 16	9 / 241 (3.73%) 9	11 / 204 (5.39%) 13
Skin and subcutaneous tissue disorders			
Erythema subjects affected / exposed occurrences (all)	130 / 271 (47.97%) 179	182 / 241 (75.52%) 369	89 / 204 (43.63%) 162
Psychiatric disorders			
Irritability subjects affected / exposed occurrences (all)	142 / 271 (52.40%) 181	207 / 241 (85.89%) 428	152 / 204 (74.51%) 272
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 271 (0.00%) 0	18 / 241 (7.47%) 19	11 / 204 (5.39%) 14
Otitis media subjects affected / exposed occurrences (all)	22 / 271 (8.12%) 23	25 / 241 (10.37%) 26	19 / 204 (9.31%) 23
Rhinitis			

subjects affected / exposed occurrences (all)	25 / 271 (9.23%) 29	21 / 241 (8.71%) 25	36 / 204 (17.65%) 43
Upper respiratory tract infection subjects affected / exposed occurrences (all)	40 / 271 (14.76%) 47	38 / 241 (15.77%) 46	50 / 204 (24.51%) 67
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 271 (0.00%) 0	9 / 241 (3.73%) 9	12 / 204 (5.88%) 13
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	118 / 271 (43.54%) 140	153 / 241 (63.49%) 217	105 / 204 (51.47%) 159

<b>Non-serious adverse events</b>	10Pn2+1-6W-6M/053 Group	10Pn12-18M/053 Group	
Total subjects affected by non-serious adverse events subjects affected / exposed	1295 / 1316 (98.40%)	354 / 368 (96.20%)	
Nervous system disorders Somnolence subjects affected / exposed occurrences (all)	1024 / 1316 (77.81%) 1876	214 / 368 (58.15%) 281	
General disorders and administration site conditions Injection site induration subjects affected / exposed occurrences (all)	239 / 1316 (18.16%) 340	45 / 368 (12.23%) 52	
Pain subjects affected / exposed occurrences (all)	983 / 1316 (74.70%) 1830	301 / 368 (81.79%) 463	
Pyrexia subjects affected / exposed occurrences (all)	688 / 1316 (52.28%) 1062	119 / 368 (32.34%) 143	
Swelling subjects affected / exposed occurrences (all)	878 / 1316 (66.72%) 1594	209 / 368 (56.79%) 290	
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	78 / 1316 (5.93%)	26 / 368 (7.07%)	
occurrences (all)	86	28	
Teething			
subjects affected / exposed	40 / 1316 (3.04%)	0 / 368 (0.00%)	
occurrences (all)	45	0	
Vomiting			
subjects affected / exposed	0 / 1316 (0.00%)	0 / 368 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 1316 (0.00%)	14 / 368 (3.80%)	
occurrences (all)	0	16	
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	1042 / 1316 (79.18%)	265 / 368 (72.01%)	
occurrences (all)	2077	398	
Psychiatric disorders			
Irritability			
subjects affected / exposed	1204 / 1316 (91.49%)	283 / 368 (76.90%)	
occurrences (all)	2592	407	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	49 / 1316 (3.72%)	0 / 368 (0.00%)	
occurrences (all)	59	0	
Otitis media			
subjects affected / exposed	32 / 1316 (2.43%)	25 / 368 (6.79%)	
occurrences (all)	34	29	
Rhinitis			
subjects affected / exposed	74 / 1316 (5.62%)	29 / 368 (7.88%)	
occurrences (all)	88	33	
Upper respiratory tract infection			
subjects affected / exposed	109 / 1316 (8.28%)	36 / 368 (9.78%)	
occurrences (all)	122	37	
Gastroenteritis			

subjects affected / exposed occurrences (all)	0 / 1316 (0.00%) 0	0 / 368 (0.00%) 0	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	713 / 1316 (54.18%) 1072	191 / 368 (51.90%) 238	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 December 2008	Protocol amendment 1, dated 11 December 2008, implemented the following: 1) Addition of 6 clusters located in municipalities where no agreement from the health care center responsible for the municipality primary health care and well-baby clinics had been obtained for participation in the 10PN-PD-DIT-043 study (i.e. Espoo, Vantaa and surroundings municipalities); 2) The addition of a nasopharyngeal swab sampling at the pre-vaccination time point for subjects enrolled within the first 7 months of life and who were part of the Immuno subset and for all subjects enrolled between 7-11 months of age.; 3) Recording of Bacille Calmette Guerin (BCG) vaccination since birth up to 30 days before the first study vaccination; 4) The addition of a sample size justification for acute otitis media (AOM) endpoint; 5) The addition of Infanrix Polio+Hib vaccine as a non-study vaccine to be offered to all subjects in order to comply with the national immunization recommendations; 6) The addition of Rotarix as a non-study vaccine to be offered to children within the first 6 months of life; 7) Physical examination was made optional after Visit 1 (screening), 8) Attribution of a treatment number was added as a study procedure for each vaccination visit.
18 February 2009	Protocol amendment 2, dated 18 February 2009, implemented the following changes: 1) Addition of collection of data on respiratory tract infections (RTIs), including detailed acute otitis media (AOM) diagnosis data in a subset of subjects in Turku area; 2) Inclusion of municipalities surrounding Oulu in the list of municipalities where no collaboration with health care centers had been set up in study 10PN-PD-DIT-043 but where there was opportunity for parent(s)/LARs to let their child participate in study 10PN-PD-DIT-053 (i.e. Espoo, Vantaa and surroundings municipalities and municipalities surrounding Oulu); 3) The National Public Health Institute (KTL) and the National Research and Development Centre for Welfare and Health (STAKES) had merged to the National Institute for Health and Welfare (THL); 4) Clarification was added in some tables concerning the age at enrolment; 5) Correction of the interval between some study visits; 6) Wording concerning the Immuno subset was changed to ensure that the subjects in this subset would be enrolled according to the age and treatment groups; 6) Deletion of the specification of the injection side.
17 November 2009	Protocol amendment 3, dated 17 November 2009, implemented the following change. Because a higher number of non-evaluable subjects for according-toprotocol (ATP) analysis due to the flu pandemic in 2009 was anticipated and the recruitment rate was lower than expected, especially in the catch-up cohorts (7-18 months of age at enrolment), the target numbers of subjects to be recruited per age group was changed and the recruitment time was extended in order to secure the AOM objective which was related to the infant vaccination cohort (< 7 months of age at enrolment) based on the ATP cohort.

12 August 2011	<p>Protocol amendment 4, dated 12 August 2011, was developed for the following reasons: 1) The conditions for triggering IPD effectiveness analysis in this study were linked to the 10PN-PD-DIT-043 study. As the 10PN-PD-DIT-043 study enrolment reached only 50% of the initial recruitment plan, there was a need to redefine the conditions for triggering IPD effectiveness analysis in that study. Consequently, this change was reflected in the 10PN-PD-DIT-053 protocol; 2) In order to align the timing of unblinding (planned after cleaning of the clinical database from both studies) with the 10PN-PD-DIT-043 study, the age range for the last study visit for subjects enrolled between 6 weeks and 6 months of age was enlarged from 21-22 months of age to 18-22 months of age; 3) The protocol was adjusted to reflect the Independent Data Monitoring Committee (IDMC) recommendation to evaluate the chest X-rays from the hospital-diagnosed pneumonia cases in this study by an independent review panel according to WHO guidelines for study purposes, as in the 10PN-PD-DIT-043 study; 4) GSK Biologicals had decided to maintain pneumococcal enzyme-linked immunosorbent assay (ELISA) testing but not to perform the pneumococcal opsonophagocytic activity (OPA) and anti-protein D ELISA testing in the 7-11 and 12-18 months of age groups part of the immuno subset for the following reasons: a) The WHO considers the antibody concentration measured by the ELISA assay as the main licensure criterion for new pneumococcal conjugate vaccines and the outcome of the OPA testing on samples obtained one month post-primary vaccination as supportive for licensure, b) These tests in the catch-up groups were not linked to the primary objective of the study, i.e. IPD effectiveness in the infant cohort; 5) Further details on microbiological testing were included and additional minor corrections were done.</p>
----------------	--

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Number allocation errors were identified for 3 subjects after Dose 1, which GSK assessed as not having significant impact. Lower & upper respiratory tract infections endpoint results are not presented, being uninterpretable due to low sample size.

Notes: